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colon, and suggests that functions of LIN28B may occur via let-7 independent mechanisms. Potentially,
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Abstract
LIN28B, LET-7, AND THE MOLECULAR PATHOGENESIS OF COLON CANCER
Catrina E. King
Anil Rustgi
Lin28b is an RNA-binding protein that inhibits biogenesis of tumor-suppressive
microRNAs of the let-7 family, and is involved in induction of pluripotency. Although
LIN28B has been implicated in cancer, a specific role in colon tumorigenesis has not been
elucidated. We have determined that colon tumors exhibit decreased levels of mature let7 isoforms, and that constitutive let-7 expression inhibits migration and invasion of colon
cancer cells in vitro. Importantly, down-regulation of let-7a and let-7b in colon tumors
correlates with increased expression of LIN28B, suggesting tumor-promoting properties
of this let-7 inhibitor. In order to determine the role of LIN28B in colon cancer, we
constitutively expressed LIN28B in immortalized human colonic epithelial cells and
colon cancer cell lines via retroviral transduction. We found that constitutive LIN28B
expression promotes migration, invasion, and soft-agar colony formation in vitro, as well
as differentiated and metastatic phenotypes in vivo. Additionally, constitutive LIN28B
expression modulates levels of several mRNA transcripts including the established let-7
targets IGF2BP1 and HMGA2. The intestinal stem cell related genes LGR5 and PROM1,
which are not predicted let-7 targets, are also up-regulated with constitutive LIN28B
expression – an effect that is not ameliorated by co-expression of let-7, thereby
suggesting possible let-7 independent functions of LIN28B. These findings are
corroborated by correlation of high LIN28B expression in colon tumors with poor patient
prognosis. In summary, this work demonstrates tumor-promoting properties of LIN28B in
the colon, and suggests that functions of LIN28B may occur via let-7 independent
mechanisms. Potentially, LIN28B may evolve as a novel diagnostic marker or therapeutic
target in colon cancer.
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Introduction

Emerging roles for LIN28B and let-7 in colon
cancer pathogenesis

1

Colorectal cancer is amongst the leading causes of cancer related deaths
Despite advances in diagnostic and therapeutic modalities, colorectal cancer
remains the third most common cause of cancer-related death amongst men and women
in the U.S. Nearly 140,000 new cases of colorectal cancer are diagnosed annually in the
United States; the disease proves fatal to nearly 60,000 patients in the U.S. and over
600,000 individuals worldwide each year (ACS, 2010; WHO, 2010). The 5-year survival
rate for patients diagnosed with early-stage, localized colorectal cancer is 91%; however,
this statistic drops precipitously to 11% for individuals with metastatic disease. Early
diagnosis is therefore critical, yet less than 40% of colorectal tumors are diagnosed in
precancerous polyp or early stages. Due to diagnostic screening, the overall number of
new colorectal cancer cases has nonetheless declined since 1985. However, incidence
rates are rising amongst individuals younger than 50, where screening is generally not
recommended except for those with hereditary syndromes (ACS, 2010). Accordingly,
improvements in diagnostic and therapeutic modalities for colorectal cancers are needed.
The vast majority (approximately 70-80%) of colorectal tumors arise via
chromosomal instability that occurs as a consequence of accumulated genetic alterations,
triggered by mutations in the APC (adenomatous polyposis coli) tumor suppressor gene.
A subset of individuals develop colorectal tumors as the result of inherited syndromes
such as hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome and
familial adenomatous polyposis (FAP) (Rustgi, 2007). Studies of these inherited forms of
colorectal cancer have offered enormous insights into the pathogenesis of sporadic
colorectal tumors (Kinzler & Vogelstein, 1996; Rustgi, 2007).
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Characteristics and functions of LIN28B
LIN28B (C. elegans lin-28 homolog B) is a homolog of LIN28 (C. elegans lin-28
homolog A), which induces pluripotency when expressed in combination with OCT4,
SOX2, and Nanog (Guo et al, 2006; Yu et al, 2007b). The 5,504 nucleotide open reading
frame of LIN28B encodes a 250 amino acid, 28 kDa protein with significant sequence
similarity to LIN28. In addition to being very similar to each other, the two proteins are
conserved across species, including C. elegans (Guo et al, 2006; Moss & Tang, 2003).
Sequence conservation occurs largely in the cold-shock and retroviral-type CCHC zinc
finger domains that confer RNA binding ability, implicating LIN28 and LIN28B in posttranscriptional gene regulation (Guo et al, 2006; Moss & Tang, 2003).
In C. elegans, lin-28 (abnormal cell LINeage family member) is a heterochronic
gene that, when mutated, causes precocious development as a result of skipping larval
stage two (L2) (Ambros & Horvitz, 1984). In lin-28 mutant C. elegans, restricted
developmental processes occur one stage earlier than normal, and the molting process
ceases at L3. Furthermore, mutant animals transition from larvae to adults in only three
developmental stages, instead of the normal four (Ambros & Horvitz, 1984). Moreover,
Lin-28 mutants are malformed and incapable of laying eggs due to abnormalities in cell
division and vulval specification (Euling & Ambros, 1996a; Euling & Ambros, 1996b).
A phenotype opposite of lin-28 mutation occurs in C. elegans let-7 microRNA
mutants. Instead of omitting stages as observed in lin-28 mutants, let-7 mutants reiterate
larval fates (Reinhart et al, 2000). This aberration occurs at the L4 to adult molt (Reinhart
et al, 2000), which would indicate a position for let-7 beneath lin-28 in the C. elegans
heterochronic gene hierarchy. However, the hierarchical placement of let-7 in relation to
3

lin-28 in C. elegans remains unclear, as lin-28 contains multiple binding sites for let-7 in
its 3’ UTR. More recent work demonstrates C. elegans lin-28 as a negative regulator of
let-7 biogenesis; this repressive activity is also critical to mammalian LIN28 and LIN28B
function.
Let-7 microRNAs are highly conserved between C. elegans and humans, and
function by binding to the 3’ UTR of target mRNAs and suppressing translation (Bartel,
2004; Lagos-Quintana et al, 2001; Pasquinelli et al, 2000; Vella & Slack, 2005). They are
transcribed initially as pri-miRNAs, and are processed subsequently in the nucleus to
hairpin molecules termed pre-miRNAs (Lee et al, 2003; Lee et al, 2002). The hairpin premiRNAs are exported from the nucleus via exportin-5, and are processed further into
their ~21 nucleotide mature form by dicer (Hutvagner et al, 2001; Yi et al, 2003). Lin28
and Lin28b bind the hairpin loop of let-7 microRNAs and recruit Zcch11, an enzyme that
uridylates pre-let-7 molecules, thereby impeding their further processing via dicermediated cleavage (Hagan et al, 2009; Heo et al, 2008). The ability of Lin28 and Lin28b
to bind pre-let-7 hairpin loops is dependent upon the RNA-binding activity conferred by
the conserved cold-shock domain and CCHC zinc fingers (Balzer et al, 2010; Moss &
Tang, 2003).
In addition to binding let-7 microRNAs and inhibiting their processing, additional
roles have been suggested for Lin28 and Lin28b in mediating post-transcriptional gene
regulation. First, Lin28, while predominantly cytoplasmic, shuttles to the nucleus in a
manner dependent upon the cold shock domain and CCHC zinc fingers (Balzer & Moss,
2007). In addition, Lin28 localizes to P-bodies, and is found in cellular stress granules,

4

suggesting a possible role in mediating translational repression of mRNAs (Balzer &
Moss, 2007).
Consistent with a role for Lin28 in initiating and/or modulating translation
efficiency, Lin28 is associated with active polysomes in myoblasts (Polesskaya et al,
2007). Lin28 co-localizes and interacts with the translation initiation factor eIF3β in
stress granules, and this association is enhanced during myoblast differentiation
(Polesskaya et al, 2007). Importantly, Lin28 binds IGF2 mRNA, driving it into
polysomes and improving translational efficiency. Lin28’s ability to up-regulate IGF2
(Insulin-like growth factor 2) has been established in both skeletal myogenesis and
neurogliogenesis (Balzer et al, 2010; Polesskaya et al, 2007).
In addition to binding IGF2, Lin28 associates with OCT4 (octamer-binding
transcription factor 4; also known as POU5F1) mRNA in ribonucleoproteins and
polysomes (Qiu et al, 2010). Oct4 is a POU-domain containing transcription factor
involved in modulating cell fate and differentiation. Increasing Oct4 levels by less than
two-fold is sufficient to stimulate embryonic stem cell differentiation into primitive
endoderm and mesoderm (Niwa et al, 2000). Correspondingly, reduction of Oct4
expression induces trophectoderm formation. Thus, Oct4 protein is modulated during
differentiation, and is a critical determinant of cell fate (Niwa et al, 2000). Interestingly,
the OCT4 gene is common to the earliest descriptions of induced pluripotency in somatic
cells. Yu et al. demonstrated induction of pluripotency through co-expression of OCT4,
SOX2, LIN28 and NANOG in fibroblasts (Yu et al, 2007b). Similarly, Takahashi et al
described a method of reprogramming somatic cells via retroviral expression of OCT4,
SOX2, KLF4, and c-MYC (Takahashi et al, 2007; Takahashi & Yamanaka, 2006).
5

Therefore, the ability to bind OCT4 mRNA and influence its transcriptional efficiency is
likely essential to the role of Lin28 and Lin28b in establishment and/or maintenance of
pluripotency.

Cellular differentiation in the colonic epithelium
Pluripotent cells have the potential to differentiate into cellular derivatives of
either endoderm, mesoderm, or ectoderm origin (De Miguel et al, 2010). During cellular
differentiation, cells become more specialized while simultaneously diminishing in stem
cell characteristics (Beddington & Robertson, 1989; Potten & Loeffler, 1990). Terminally
differentiated cells are generally non-proliferative, and exhibit a restricted gene
expression profile (Yamanaka & Blau, 2010).
Pluripotent adult stem cells in the small intestine and colon are located within
deep folds of the epithelium known as crypts of Lieberkühn, and are capable of
differentiating into any of the four major cell types that comprise intestinal epithelium
(Barker et al, 2007; Brittan & Wright, 2002; Brittan & Wright, 2004a; Brittan & Wright,
2004b; Papailiou et al, 2010; Potten et al, 1997; Potten et al, 2009; Potten & Loeffler,
1990). The majority of the intestinal epithelium is comprised of cells from the absorptive
lineage - enterocytes in the small intestine and colonocytes in the colon. These cells
function mainly in absorbing micronutrients and water from the lumen, respectively
(Cheng & Leblond, 1974a; Cheng & Leblond, 1974b; Cheng & Leblond, 1974c). The
remaining three cell types of the intestinal epithelium are part of the secretory lineage,
including Paneth, enteroendocrine, and goblet cells (Cheng & Leblond, 1974a; Cheng &
Leblond, 1974b; Cheng & Leblond, 1974c); of note, Paneth cells are not found in the
6

colon. Paneth cells reside within intestinal crypts, secrete lysosymes, and are thought to
be involved in anti-microbial functions (Ayabe et al, 2002a; Ayabe et al, 2000; Ayabe et
al, 2002b), while enteroendocrine cells secrete hormones that aid in nutrient homeostasis
(Drucker, 2007; Murphy & Bloom, 2006; Rindi et al, 2004) and are found in both the
small intestine and colon. Goblet cells secrete mucin glycoproteins that have
cytoprotective properties (Neutra et al, 1982; Phillips et al, 1984).
The terminally differentiated cells of the intestinal/colonic epithelium are shed
approximately every 5-7 days and are replaced by new cell populations emerging from
the crypts (Brittan & Wright, 2002; Brittan & Wright, 2004a; Brittan & Wright, 2004b;
Potten et al, 2009). Accordingly, stem cells in the crypt face unique challenges compared
to other adult tissues which renew with less frequency in coordinating the balance
between proliferation and differentiation (Potten et al, 2009; Reya & Clevers, 2005).
While some of the molecular mechanisms underlying regulation of cellular differentiation
in the small intestine and colon have been elucidated, a number of critical questions
remain unanswered. For example, while it is generally accepted that intestinal stem cells
reside within the crypts of Lieberkühn, the actual position of stem cells within the crypts
of the small intestine, i.e. between the Paneth cells at the base of the crypt (so called
CBCs) or immediately superior to them at position +4, is debated (Barker et al, 2007;
Brabletz et al, 2009; Potten et al, 1997; Potten et al, 2009).
In general, cellular proliferation in the intestinal epithelium is restricted to the
crypt wherein the stem cells reside, while differentiation occurs as cells migrate from the
crypt toward the surface (Paneth cells are a notable exception) (Barker et al, 2007; Potten
et al, 1997; Potten et al, 2009; Potten & Loeffler, 1990). The process by which stem cells
7

give rise to transit amplifying cells of the absorptive and secretory lineages is tightly
controlled via integration of Wnt, Notch, BMP, Hedgehog, and PI3K pathways, amongst
others (Brabletz et al, 2009). Of these pathways, canonical Wnt (wingless-related MMTV
integration site family) signaling is perhaps the most crucial, as aberrations in Wnt
signaling have profound effects on intestinal pathology, and occur frequently as early
events in colon cancer tumorigenesis (Clevers, 2006; Fearon & Vogelstein, 1990;
Korinek et al, 1997; Morin et al, 1997; Nakamura et al, 2007; Potten et al, 2009; Reya &
Clevers, 2005).

Canonical Wnt signaling: a critical pathway in the colon
In mammals, there are approximately 20 variable extracellular Wnt ligands with
both overlapping and distinct functions. Canonical Wnt signaling is typified by Wnt
ligands binding to a primary receptor and co-receptor combination, FRZ (frizzled) and
LRP-5/6 (low density lipoprotein receptor-related protein 5) respectively. Upon receptor
activation, DSH (disheveled) inhibits a complex containing axin, GSK3β , and APC; the
latter two cooperate to phosphorylate β-catenin, targeting it for ubiquitin-mediated
degradation via the proteasome (Hart et al, 1998; Reya & Clevers, 2005; Rubinfeld et al,
1996; Rubinfeld et al, 1993). Repression of the APC/GSK3β/axin complex by DSH
results in stabilization of β-catenin, which then translocates to the nucleus and activates
TCF (transcription factor) and/or LEF (lymphoid enhancer-binding factor 1) transcription
factors (Behrens et al, 1996; Morin et al, 1997). Targets of Wnt signaling include
proliferation factors such as cyclin D1 and c-myc, pluripotency factors including OCT4
and Nanog, as well as Wnt pathway components themselves (Clevers, 2006; Cole et al,
8

2008; He et al, 1998; Pereira et al, 2006; Shtutman et al, 1999; Tetsu & McCormick,
1999).
Wnt signaling is critical to maintaining the proliferative potential of the intestinal
stem cell populations within the crypts (Kim et al, 2005; Reya & Clevers, 2005); this may
occur via multiple mechanisms, but most notably via c-myc mediated repression of
p21CIP1/WAF1. An established TCF4 target, c-myc, binds the promoter of the cyclindependent kinase inhibitor p21CIP1/WAF1 repressing its transcription (van de Wetering et al,
2002). Therefore, down-regulation of c-myc via withdrawal of Wnt signaling
transcriptionally activates p21CIP1/WAF1, which subsequently mediates G1 arrest and
promotes cellular differentiation (Reya & Clevers, 2005; van de Wetering et al, 2002).

The molecular pathogenesis of colon cancer
Mutations in components of the canonical Wnt signaling pathway occur in the
majority of colorectal cancers with inactivating mutations in the APC gene being the
most common (Kinzler & Vogelstein, 1996). Germline mutations in the APC tumor
suppressor gene were originally identified as the etiologic agent in Familial Adenomatous
Polyposis or FAP (Ichii et al, 1993; Levy et al, 1994; Luongo et al, 1994). Later, it was
determined that sporadic mutations in APC are the most common known genetic
perturbations (70-80%) identifiable in early adenomatous polyps that may progress to
cancer (Kinzler & Vogelstein, 1996; Lamlum et al, 2000; Powell et al, 1992; Rowan et al,
2000). Following truncating mutations in APC, activating point mutations in KRAS (VKi-ras2 Kirsten rat sarcoma viral oncogene homolog) are the most common genetic
perturbation (40-50%) identified in the progression of adenomatous polyps to cancer;
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tumor suppressor genes (p53 and SMAD3/4) are often mutated in later stage tumors
(Fearon & Vogelstein, 1990; Kinzler & Vogelstein, 1996; Kressner et al, 1998).
A linear model of the molecular pathogenesis of colon cancer was developed
originally by Bert Vogelstein et al. (Fearon & Vogelstein, 1990). Vogelstein’s widely
accepted model of colon cancer pathogenesis describes an accumulation of genetic
alterations that correspond to progression from normal to hyperproliferative epithelium,
adenomas, cancers and finally, metastasis. Truncating mutations in APC occur in the
earliest phases, and are the paramount initial step toward hyperproliferation in colonic
epithelium. Hyperproliferative foci of intestinal epithelial cells result in adenomatous
polyps, and may acquire activating mutations in KRAS. Loss of SMAD4 and p53
accompany progression to late stage adenomas, and accumulated mutations eventually
result in colon cancer development and metastasis.
It is important to note that various pathways for colon cancer initiation exist in the
colon. For example, serrated polyps (including hyperplastic polyps, admixed hyperplastic
polyps/adenomas, and sessile serrated adenomas) may represent a mode of cancer
development distinct from the archetypal adenoma-carcinoma sequence (Hawkins et al,
2002; He et al, 1998; Huang et al, 2004). Thus, the mechanisms involved in colon cancer
pathogenesis are yet to be fully elucidated, but an unrelenting effort is being made to
close this knowledge gap.

Potential roles for LIN28B in colon cancer pathogenesis
The c-myc transcription factor is a Wnt pathway target that is frequently
overexpressed in colon cancers (Chan et al, 1987; He et al, 1998; Sikora et al, 1987;
10

Stewart et al, 1986). C-myc transcriptionally activates LIN28B, and this activity is a
necessary mediator for at least a subset of c-myc functions (Chang et al, 2009); it remains
to be determined whether Lin28b mediates a portion of c-myc-induced activities that
promote tumorigenesis in the colon. Additionally, since KRAS is an established let-7
target, LIN28B overexpression may up-regulate KRAS activity via repression of let-7
biogenesis (Jeong et al, 2009; Johnson et al, 2005).
To date, despite divergences in amino acid sequences, molecular or biochemical
functions unique to either Lin28 or Lin28b have not been determined. However, while
overexpression of both LIN28 and LIN28B occurs in multiple cancers, LIN28B
overexpression has been demonstrated in specific cancers more frequently. For example,
LIN28B is overexpressed in hepatocellular carcinomas (Guo et al, 2006). More
interestingly, a broad analysis of LIN28 and LIN28B expression in various tumors and
cell lines conducted by Viswanathan et al. pointed to LIN28B as perhaps the more
relevant homolog in tumorigenesis. Viswanathan et al. implicated a role for LIN28B in
Wilms’ tumors where the c-myc binding site on LIN28B’s promoter is frequently
demethylated and chronic myeloid leukemia where expression of LIN28B occurs more
commonly in blast crisis. In addition, Viswanathan et al. demonstrated LIN28B
overexpression in non-small cell lung cancer, breast cancer, melanoma, while aberrations
in LIN28 expression were not as readily identifiable (Viswanathan et al, 2009).

We have hypothesized that LIN28B promotes tumorigenesis via repression of let7 in the colon. In formulating this hypothesis, we first demonstrated decreased expression
of let-7 in colon tumors, and identified potential tumor-suppressive functions of let-7 in
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colon cancer cells in vitro. Our initial findings, which indicate that let-7 microRNAs
repress migration and invasion of colon cancer cells in vitro, will be discussed in Chapter
1. As the role of let-7 was elucidated further, mounting evidence pointed to a significant
role of Lin28b in colon tumorigenesis, in part, due to its ability to post-transcriptionally
regulate let-7. Accordingly, we constitutively expressed LIN28B in immortalized
epithelial and colon cancer cells in vitro, and found that Lin28b promotes migration,
invasion, and transformation in colon cancer cells, as described in Chapter 2.
Interestingly, our in vitro findings suggested let-7 independent functions of LIN28B,
which we further evaluated in vivo. Via constitutive expression of LIN28B in xenograft
tumors, we have identified potential functions of LIN28B in modulating differentiation
programs and promoting metastasis in colon cancers. These in vivo findings will be
detailed in Chapter 3, followed by an in-depth discussion of the broader implications of
this work, and potential future directions.
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Specific Aims

Hypothesis: LIN28B promotes tumorigenesis via
suppression of let-7 in the colon

13

The overarching hypothesis of this thesis is that LIN28B promotes tumorigenesis via
suppression of let-7 in the colon. This hypothesis has been pursued by the following
inter-related specific aims:

Specific Aim #1: To demonstrate tumor-suppressive functions of let-7 in colon
cancer.
The let-7a-3-b microRNA cluster is transcribed from a region on chromosome 22q13.31
that undergoes LOH in colon cancer. We measured mature microRNA levels in colon
tumors compared to normal colonic epithelium and found that let-7a and let-7b are
reduced in about two-thirds of tumors. Given that let-7 is reduced in a subset of colorectal
cancers, we hypothesized that re-introduction of let-7 in colon tumors suppresses
tumorigenesis. We tested this hypothesis by constitutively expressing the bicistronic let7a-3-b cluster in multiple colon cancer cell lines via retroviral transduction.
Subsequently, we evaluated colony formation in soft agar, and assessed changes in
migration and invasion via in vitro Boyden chambers assays.

Specific Aim #2: To determine the role of LIN28B in promoting colon cancer in
vitro.
Several lines of evidence suggest that let-7 microRNAs are primarily regulated through
post-transcriptional inhibition of processing. The let-7 inhibitor LIN28B is overexpressed
in various cancers, including colorectal adenocarcinomas. We hypothesized that LIN28B
promotes tumorigenesis in the colon in a let-7 dependent manner. To test this hypothesis,
we expressed LIN28B in immortalized colonic epithelial and colon cancer cell lines. We
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then assayed cell migration, invasion, and soft-agar colony formation. In addition, we
evaluated gene expression in LIN28B-expressing via microarray analysis.

Specific Aim #3: To evaluate the role of LIN28B in colon tumorigenesis in vivo.
Previous work suggests LIN28B is a potential therapeutic and/or diagnostic target,
necessitating additional analysis of LIN28B functions in vivo. In order to elucidate further
in vivo functions of LIN28B in tumorigenesis, we xenografted colon cancer cells
constitutively expressing LIN28B into nude mice, where we analyzed tumor growth and
overall architecture. Additionally, we conducted a microarray analysis in order to expose
novel mechanisms whereby LIN28B may promote tumor formation and/or progression.
Finally, we sought to determine whether LIN28B overexpression correlates with reduced
survival of patients diagnosed with colorectal adenocarcinomas. To this end, we
measured Lin28b levels in tumors and normal mucosa via immunostaining.

15

Chapter 1

Reintroduction of let-7 suppresses migration and
invasion in colon cancer cell lines
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Background and Significance
The vast majority of colorectal tumors arise via chromosomal instability,
acquiring gross chromosomal aberrations that frequently result in deletion of tumor
suppressor genes (Lengauer et al, 1997). Our lab previously identified a minimal region
of deletion on chromosome 22q13.31 in nearly 30% of colorectal tumors (Castells et al,
1999). Allelic loss on chromosome 22q is also found in tumors of the breast, ovary, oral
cavity, endocrine pancreas, and brain (Allione et al, 1998; Bryan et al, 1996; Castells et
al, 2000; Chung et al, 1998; Miyakawa et al, 1998; Rey et al, 1993). Of note, we found
that two microRNAs of the let-7 family, let-7a-3 and let-7b, are transcribed as a
bicistronic cluster from their locus on chromosome 22q13.31 (Griffiths-Jones, 2004;
Griffiths-Jones et al, 2006; Griffiths-Jones et al, 2008; mirBase, 2010).
MicroRNAs are 20-22 nucleotide molecules that inhibit translation by
complimentary binding to the 3’ UTR of target mRNA transcripts (Bartel, 2004; LagosQuintana et al, 2001). A large number of genes bear putative microRNA binding sites,
and it is postulated that microRNAs may regulate up to one-third of the genome
(Esquela-Kerscher & Slack, 2006; Lewis et al, 2005). MicroRNAs are frequently found
clustered as unique polII transcriptional units or are encoded within the introns of
protein-coding genes (Lagos-Quintana et al, 2001). They are transcribed initially as primiRNAs, and are subsequently processed in the nucleus to hairpin molecules termed premiRNAs (Lee et al, 2003; Lee et al, 2002). The hairpin pre-miRNAs are exported from
the nucleus via exportin-5, and are further processed into their ~21 nucleotide mature
form by dicer (Hutvagner et al, 2001; Yi et al, 2003).
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One of the most highly conserved families of microRNAs is that of let-7
(Pasquinelli et al, 2000). There are twelve let-7 mammalian orthologs of the four let-7
family members described in C. elegans (Vella & Slack, 2005). Let-7 microRNAs are
relatively homogenous, and a single family member may possess multiple isoforms in the
genome. Accordingly, let-7a-3 is one of three let-7a isoforms that exists in mammals, and
the mature sequence of let-7a differs from let-7b by only two nucleotides (mirBase,
2010).
A number of studies suggest that let-7 microRNAs coordinate distinctive cellular
processes, including proliferation (Johnson et al, 2007; Peng et al, 2008), and
differentiation (Johnson et al, 2007; Shell et al, 2007; Tsonis et al, 2007; Yu et al, 2007a).
Intriguingly, a bioinformatics study suggested that let-7 suppresses a number of genes
which are down-regulated toward the completion of embryogenesis, but then reexpressed in tumors (Boyerinas et al, 2008). A number of let-7 targets demonstrate an
ability to participate in tumorigenesis. For example, the canonical let-7 target HMGA2
(High-mobility group AT-hook 2) is known to drive epithelial-mesenchymal transition,
and to promote invasion and metastasis (Fabjani et al, 2005; Langelotz et al, 2003;
Motoyama et al, 2008; Park et al, 2007; Thuault et al, 2006). Additional let-7 targets
include the cell cycle regulatory protein, CDC34 (cell division cycle 34 homolog), and
the oncofetal gene IGF2BP1 (Insulin-like growth factor 2 mRNA-binding protein 1)
(Boyerinas et al, 2008; Legesse-Miller et al, 2009).
Expression of let-7 isoforms is reduced in a number of human malignancies, and
let-7 microRNAs exhibit tumor suppressive functions in a variety of cancers, most
notably non-small cell lung and breast cancers (Akao et al, 2006; Esquela-Kerscher &
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Slack, 2006; Kumar et al, 2008; Shell et al, 2007; Takamizawa et al, 2004; Viswanathan
et al, 2008; Yu et al, 2007a). Moreover, reduced let-7 expression correlates particularly
well with poorly-differentiated tumors, and thus serves as an excellent prognostic marker
(Shell et al, 2007; Takamizawa et al, 2004; Yu et al, 2007a).

Let-7a-3 and let-7b are clustered within an intron of an unnamed gene and
transcribed together from a locus on 22q13.31. Since let-7 isoforms exhibit tumorsuppressive functions in other cancers, we hypothesized that let-7a-3 and let-7b suppress
tumorigenesis within the colon. To test this hypothesis, we first assayed levels of mature
let-7 in paired normal colon and colon cancers. We found that both let-7a-3 and let-7b are
reduced in 32 of 40 colon tumors we assayed (approximately two-thirds). In order to
further elucidate the role of let-7a-3 and let-7b in colon tumorigenesis, we expressed a
pri-microRNA derived from the genomic sequence encoding the two isoforms in colon
cancer cell lines via retroviral transduction. We found that overexpression of let-7a and
let-7b in colon cancer cells repressed cellular migration and invasion in vitro. In longterm assays, we found the increase in mature let-7 to be ameliorated in cells transduced
with retrovirus, likely as a consequence of endogenous post-transcriptional regulatory
mechanisms.
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Experimental Procedures
Human tissue samples. Human colorectal cancer and adjacent normal colon
tissues were obtained from a collaborator (Dr. Naomoto) from the Department of
Surgery, Okayama University Medical School, Japan under Institutional Review Board
approval. Normal and tumor colon samples were stored initially in RNAlater at -80o C.
Tumor tissue were homogenized mechanically on ice and fine particulates were collected
via centrifugation at 4o C. RNA was isolated from homogenized tissues using a mirVana
RNA isolation kit (Ambion, Austin, TX) and evaluated for integrity using a Bioanalyzer
(Agilent, Santa Clara, CA).

Mature microRNA detection in human tumors and transduced cells. Total
RNA was extracted from human tissues, transfected 293T, or transduced LIM 2405 and
LoVo cells using the mirVana miRNA isolation kit (Ambion, Austin, TX). Taqman®
MicroRNA Assay kits for both let-7a and let-7b (Applied Biosystems, Carlsbad, CA)
were employed to synthesize probe-specific cDNA from 10ng of total RNA per sample.
Levels of mature microRNAs were measured via qPCR on the ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Carlsbad, CA). Probe-specific cDNA was
amplified using proprietary primers (Applied Biosystems, Carlsbad, California) and
TaqMan® Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems,
Carlsbad, CA). PCR amplifications were performed in triplicate and normalized to levels
of endogenous U47. Fold change for let-7a and let-7b was determined by normalization
to empty vector controls. Statistical significance of comparisons between empty vector
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and let-7a-3-b was determined by applying student’s t-test, with p<0.05 considered
significant.

Detection of let-7a3-b pri-microRNA. Total RNA was extracted from human
tissues, transfected 293T, or transduced LIM 2405 and LoVo cells using the mirVana
miRNA isolation kit as described above. cDNA was synthesized from 5 μg total RNA per
sample using random hexamers and SuperScript II Reverse Transcriptase (Invitrogen,
Carlsbad, CA). Detection of let-7a3-b pri-microRNA intronic sequence was achieved
using primers specific to the intronic sequence between let-7a-3 and let-7b which bear
the following sequences: ggggccgcctacactgagaag and ctggggcacgtgctgggaacct. Fold
change for let-7a-3-b were determined by using Image J analysis to quantify individual
band intensities, followed by normalization to empty vector controls.

Biostatistical analysis of let-7 expression in human tissues. The distributions of
let-7a and let-7b fold change were right-skewed, hence a log-transformation was used to
achieve approximate normality. Pearson correlation coefficients were calculated to
assess the strength of the linear association between let-7a and let-7b, let-7 expression
and tumor stage, and let-7 expression and survival. Statistical significance of
comparisons between empty vector and LIN28B transduced cells in migration, invasion,
soft-agar assays were determined by applying student’s t-test.

Retroviral expression vector construction. A ~1.1 kb sequence containing let7a3-b cluster pri-microRNA was amplified from chromosome 22q31.31 in normal human
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colonic epithelial cells using primers with the aforementioned sequences. The ~1.1kb
clone was subcloned into a self-contained tetracycline-inducible vector designated
pBSTR1 (Paulus et al, 1996) via restriction digest with SnaBI and EcoRI enzymes (New
England Biolabs, Ipswich, MA) followed by blunt end ligation with T4 DNA ligase
(Invitrogen, Carsblad, CA). Proper orientation of insert and absence of mutations was
confirmed via sequencing at The University of Pennsylvania’s DNA sequencing facility.

Virus packaging and transient expression of let-7a-3-b in 293T cells. 30μg of
the pBSTR1-let-7a-3-b plasmid construct was transfected into 293T cells using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA), as per the protocol. Transfection
efficiency was determined by detection of GFP protein expression via light microscopy.
Supernatant containing viral particles was collected every 24 hours, filtered through a
0.45μm membrane, and immediately placed in liquid nitrogen. Viral supernatants were
stored at -80o C prior to use. 293T cells utilized in viral packing were harvested by
scraping in PBS over ice and stored at -80o C for subsequent RNA and protein isolation.

Western blot analysis. Cells were lysed in RIPA buffer containing protease
inhibitor cocktail (Roche Diagnostics, Manheim Germany). Cellular debris was removed
from lysates via centrifugation, and protein was quantitated via the BCA Protein Assay
Kit (Thermo Scientific, Rockford, IL). 20 μg total protein was loaded onto 4-12%
gradient gels for electrophoresis in NuPAGE® Running Buffer (Invitrogen, Carlsbad,
CA) using an Invitrogen (Carlsbad, CA) western blotting apparatus. Proteins were
transferred in NuPAGE® Transfer Buffer to PVDF membranes per Invitrogen protocol,
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at 20 V overnight. The following day, membranes were blocked in 5% non-fat milk in
TBS-T, and blotted with Lin28b (1:100) (Abcam, Cambridge, MA) or β-actin (1:1000)
(Sigma-Aldrich, St. Louis, MO) primary antibodies as per the manufacturer’s protocol.
Lin28b and β-actin were detected using secondary rabbit (1:1000) and mouse (1:1000)
antibodies respectively. Visualization of detected proteins on film using Amersham ECL
Plus™ Western Blotting Detection Reagents (GE Healthcare, Fairfield, CT).

Generation of colon cancer cell lines constitutively expressing let-7a-3-b.
Inducible expression of let-7a-3 and let-7b in colon cancer cell lines was achieved by
transducing LIM2405 and LoVo cells. Prior to transduction, viral-containing media was
decanted from 293T cells transfected with pBSTR1-let-7a-3-b plasmid. Viral supernatant
plus polybrene (4 μg/ml) was applied to cells, which were then subjected to
centrifugation at 1000g for 90 minutes. Inoculated cells were selected in puromycin, and
changes in mature let-7a and let-7b were detected using the mature microRNA detection
strategy described above. Expanded cell cultures were maintained in DMEM plus 10%
FBS at 37o C, 5% CO2.

Boyden chamber migration and invasion assays. Invasion assay inserts (BD
Biosciences, San Jose, California) were rehydrated in tissue culture incubators for 2 hours
with 500μl serum-free DMEM prior to use. Cells were trypsinized, washed with PBS and
resuspended in serum-free DMEM. 50,000 cells per well were plated in the upper
chamber of fluorescent transwell assay systems atop a migration insert (BD Biosciences,
San Jose, California) or a rehydrated invasion assay insert (BD Biosciences, San Jose,
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California) in a final volume of 500μl. 750μl complete media (DMEM + 10% FBS) was
added to the lower chamber as a chemoattractant. The assay system was incubated at 37o
C, 5% CO2 overnight. Assay inserts were washed in PBS, then stained with calcein AM
(4 μg/ml). Fluorescence was detected at 580nm using a plate reader as per the
manufacturer’s protocol.
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Results
Colon tumors exhibit reduced mature let-7a and let-7b levels
We compared mature let-7a and let-7b microRNA levels in normal colonic
epithelium versus adjacent colonic tumors. RNA was harvested from tissues and utilized
to generate the probe-specific cDNA necessary to quantitate the mature let-7 isoforms via
qPCR. In approximately two-thirds of the tumors assayed, we found a greater than 60%
reduction in let-7 levels when compared to adjacent normal colonic epithelium (Table 1;
Figure 1). Importantly, let-7a and let-7b are the primary let-7 isoforms expressed in the
normal colon, thus simultaneous reduction in their expression could have potential broad
consequences in colon cancer. Though mature let-7a and let-7b levels correlate with one
another (Pearson correlation coefficient, r = 0.84; p<0.0001), they do not statistically
correlate with tumor stage or probability of survival (data not shown).

Constitutive let-7a-3-b expression inhibits cell migration and invasion
In order to elucidate the functions of let-7a-3 and let-7b in colon tumors, we
subcloned let-7a-3-b pri-microRNA into a self-contained, tetracycline-inducible,
retroviral expression vector. We then transiently transfected 293T cells with let-7a-3-b
expression and measured mature let-7a and let-7b in transfected cells. Constitutive let-7a3-b pri-microRNA expression increases levels of both let-7a and let-7b mature
microRNAs by more than 8 fold (Figure 2a). Furthermore, increases in let-7a and let-7b
decreases protein levels of known let-7 targets, including HMGA2, CDC34, and
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IGF2BP1 (Figure 2b); this confirms processing of exogenously expressed let-7a-3-b into
functionally mature let-7a and let-7b microRNAs.
We then transduced LIM 2405 and LoVo colon cancer cell lines using retroviruscontaining media generated from transfected 293T cells. LIM 2405 and LoVo cells were
selected because they display the lowest levels of let-7a and let-7b compared to several
other colon cancer cell lines tested (data not shown). We confirmed a more than two-fold
increase in mature let-7a and let-7b levels via RT-qPCR with constitutive expression of
let-7a-3-b in LIM 2405 and LoVo cells (Figure 3a). Subsequently, we subjected LIM
2405 and LoVo cells transduced with let-7a-3-b to migration and invasion assays. We
found that colon cancer cells with increased let-7a and let-7b exhibited reduced migration
and invasion compared to the cell lines with empty vector controls (Figure 3b-c).

Processing of let-7a-3-b pri-microRNA into mature let-7a and let-7b
declines over time
Next, we sought to determine the effects of let-7a and let-7b overexpression on
cellular proliferation in LIM 2405 and LoVo cells. Contrary to our hypothesis, we did not
observe significant differences in cellular proliferation between empty vector and let-7a3b-expressing cells on WST (water-soluble tetrazolium salt) proliferation assays (data not
shown). This prompted re-evaluation of let-7 expression in LIM 2405 and LoVo cells
transduced with let-7a-3-b retrovirus. We measured mature let-7a and let-7b levels in let7a-3-b transduced cells that had undergone 6 passages. Surprisingly, we observed
reduced levels of let-7a and let-7b mature microRNAs in let-7a-3-b-expressing cells
compared to empty vector controls (Figure 4). The change in mature let-7a and let-7b
27

levels is perhaps attributable to decreased post-transcriptional let-7 processing,
suggesting activation of let-7 inhibitors, namely LIN28B.
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Figure 1

Reduction of mature let-7a and let-7b levels in colon tumors compared to adjacent
normal colon. Representative analysis of 5 tumors (T) matched with adjacent normal
colonic epithelia (N). RNA was isolated from normal and tumor epithelia and pairs
assayed for mature let-7a and let-7b via quantitative real-time PCR (RT-qPCR). Each
pair is normalized to mature let-7a and let-7b levels in normal colonic epithelium (N).
Mature let-7a and let-7b levels correlate with each other (Pearson correlation coefficient,
r = 0.84; p<0.0001).
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Table 1

Fold Expression

Tumors

>1.2

3

1.2-0.6

9

< 0.6

20

Total

32

Mature let-7a and let-7b levels are reduced in colon tumors. Summary of qPCR data
for 32 pairs of tumors matched with adjacent normal colonic epithelia. RNA was isolated
from tissues and quantitative real-time RT-PCR was performed to determine levels of
mature let-7a and let-7b microRNAs; let-7a and let-7b levels in tumors were normalized
to normal colonic epithelia counterparts. Mature let-7a and let-7b levels correlate with
each other (Pearson correlation coefficient, r = 0.84; p<0.0001), and are concomitantly
reduced in 20 of 32 (nearly two-thirds) of colon tumors as compared to normal colon.
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Figure 2

Constitutive let-7a-3-b pri-microRNA expression increases levels of mature let-7a
and let-7b microRNAs and represses let-7 targets. (A) Increased levels of mature
let-7a and let-7b in transfected 293T cells. RNA was isolated from 293T cells
transfected with let-7a-3-b, RT-qPCR was performed to determine mature let-7a and
let-7b levels. Constitutive expression of let-7a-3-b pri-microRNA increases cellular
levels of mature let-7a and let-7b isoforms. (B) let-7a-3-b expression represses let-7
targets. Western blot was performed to assess protein levels of let-7 targets in
transfected 293T cells. Increased mature let-7a and let-7b levels reduce expression of
let-7 targets.
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Figure 3

Reintroduction of let-7 suppresses migration and invasion in colon cancer cell lines.
(A) Increased levels of mature let-7a and let-7b in transduced LIM 2405 and LoVo cells.
RNA was isolated from LIM 2405 and LoVo cells transduced with let-7a-3-b, and mature
let-7a and let-7b levels detected via RT-qPCR. let-7a-3-b expression increases levels of
mature let-7a and let-7b isoforms by more than two-fold. (B & C) Reduced cell
migration and invasion with increased let-7. Let-7a-3-b expressing LoVo cells were
subjected to in vitro Boyden chamber migration assays. Increased mature let-7a and let7b reduces migration and invasion of LoVo cells.
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Figure 4

Processing of let-7a-3-b into mature let-7a and let-7b declines with serial passage.
RNA was isolated from passaged LIM 2405 and LoVo cells transduced with let-7a-3-b;
mature let-7a and let-7b was detected via RT-qPCR. Though mature let-7a and let-7b
levels are initially increased, they are reduced as compared to empty vector controls after
passaging.
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Chapter 1 Summary
We have demonstrated reduced mature let-7a-3 and let-7b levels in approximately twothirds of colon tumors evaluated when compared to adjacent normal colonic epithelium.
In addition, we enhanced mature let-7a and let-7b levels in colon cancer cell lines via
constitutive expression of a pri-microRNA, and observed repression of let-7 targets, apart
from suppressed cellular migration and invasion. Interestingly, we observed reduction of
mature let-7 levels with passaging of cells transduced to constitutively express let-7a and
let-7b pri-microRNA. This is perhaps due to post-transcriptional regulation. The best
characterized mechanisms of post-transcriptional regulation of let-7 involve the RNAbinding proteins Lin28 and Lin28b. Lin28b has been frequently implicated in cancer, and
is over-expressed in colon tumors. The data presented in the following chapter reveals
oncogenic properties of Lin28b, which are, in part, attributable to Lin28b’s ability to
repress let-7 biogenesis.
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Chapter 2

LIN28B promotes transformation, migration and
invasion in colon cancer cells
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Background and Significance
Currently, Lin28 and Lin28b are the best characterized post-transcriptional
repressors of let-7. Both proteins are capable of inhibiting let-7 biogenesis at the primicroRNA and pre-microRNA stages. Both Lin28 and Lin28b may impede processing of
let-7 precursors by mediating their terminal uridylation via recruitment of the enzyme
Zcch11. The addition of uridine nucleotides to let-7 pre-microRNAs disrupts dicermediated cleavage, thereby blocking the formation of mature let-7 microRNAs (Hagan et
al, 2009; Heo et al, 2008; Heo et al, 2009).
Several established let-7 targets are oncogenic, including the canonical target
HMGA2 (Lee & Dutta, 2007; Mayr et al, 2007; Park et al, 2007) and the classic
oncogenes KRAS and c-MYC (Akao et al, 2006; Johnson et al, 2007; Johnson et al, 2005).
In addition, tumor-suppressive functions have been attributed to let-7 isoforms, which are
frequently down-regulated in diverse cancers, and serve also as prognostic factors (Akao
et al, 2006; Shell et al, 2007; Takamizawa et al, 2004). Given the tumor-suppressive
properties of let-7 microRNAs, tumor-promoting properties would be predicted for their
inhibitors, namely LIN28 and LIN28B. Multiple lines of evidence suggest a role for
LIN28B in tumorigenesis. For example, LIN28B has been implicated in hepatocellular
carcinoma (Guo et al, 2006). A recent study reveals LIN28B induces transformation and
epithelial-mesenchymal transition, thereby promoting migration and invasion in
hepatocellular carcinoma cells (Wang et al, 2010). Moreover, a broad analysis of various
cancers reveals frequent LIN28B overexpression (Viswanathan et al, 2009). More
specifically, LIN28B may be involved in colon carcinogenesis since it is a direct target of
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c-myc (Chang et al, 2009). Nearly 70% of colorectal tumors exhibit elevated c-myc
levels; upregulation occurs in the early stages of colon carcinoma as a consequence of
Wnt pathway deregulation and β-catenin stabilization (Erisman et al, 1985; He et al,
1998; Sikora et al, 1987; Stewart et al, 1986).
LIN28B may promote tumorigenesis in the colon via derepression of multiple
oncogenic let-7 targets. Thus, potential functions of LIN28B in colorectal tumorigenesis
may be deduced based upon the tumorigenic properties of known let-7 targets. Although
there are several let-7 microRNAs, and each isoform is complementary to multiple target
mRNA 3’ UTRs, some targets are unique in that their let-7 binding sites exhibit perfect,
or near perfect sequence complementarity to let-7. Two such targets include HMGA2 (the
first to be characterized, and thus canonical let-7 target) and IGF2BP1 (Boyerinas et al,
2008; Lee & Dutta, 2007; Mayr et al, 2007; Park et al, 2007); both of these targets have
described roles in cancer progression (Berlingieri et al, 1995; Boyerinas et al, 2008;
Fedele et al, 1998).
HMGA2 (High mobility group A2; also known as HMGI-C) is a transcription
factor belonging to a family of HMGA proteins. HMGA2 and other HMGA family
members are overexpressed in a number of cancers, most notably ovarian cancer where a
role for HMGA2 is well described (Abe et al, 2003; Finelli et al, 2002; Park et al, 2007;
Pierantoni et al, 2005). HMGA2 promotes anchorage-independent proliferation and
induces neoplastic transformation of NIH3T3 fibroblasts (Berlingieri et al, 1995; Fedele
et al, 2002; Fedele et al, 1998).
IGF2BP1 (Insulin-like growth factor 2 mRNA-binding protein 1) is a member of
the IGF-II mRNA-binding protein (IMP) family; these proteins bind the 5' UTR of IGF2
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(insulin-like growth factor 2) transcripts, thus stabilizing IGF2 mRNA and regulating its
translation (Nielsen et al, 1999). IGF2BP1 promotes cellular motility, a property which is
perhaps critical to its role in embryogenesis and ability to promote tumorigenesis
(Boyerinas et al, 2008).

Based upon the work presented in Chapter 2, we surmised that a posttranscriptional regulator of let-7 is involved in the molecular pathogenesis of colon
cancer. We hypothesized the known let-7 inhibitor LIN28B promotes oncogenesis via
suppression of let-7 in the colon. Given that key let-7 targets HMGA2 and IGF2BP1
function in promoting anchorage-independent growth and cellular motility, we further
hypothesized that LIN28B promotes cellular migration, invasion, and transformation of
colonic epithelial cells via inhibition of let-7.
In order to elucidate the role of LIN28B in colon tumorigenesis, we first evaluated
LIN28B expression and let-7a and let-7b levels in tumors paired with adjacent normal
colonic epithelium. We found a correlation between increased LIN28B expression and
decreased let-7a and let-7b mature microRNAs. Subsequently, we constitutively
expressed LIN28B in immortalized colonic epithelial and human colon cancer cell lines.
We found that LIN28B expression increases cell migration, invasion, and soft-agar
colony formation. However, these phenotypes are only reversed partially by concomitant
let-7 expression, thereby suggesting potential let-7 independent functions of LIN28B. To
pursue this possibility, we conducted a microarray analysis that revealed several genes
up-regulated with LIN28B constitutive expression in colon cancer cells. These genes
include the intestinal stem cell markers LGR5 and PROM1 - both remain elevated
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following let-7 restoration, and thus may be regulated by LIN28B in an indirect or let-7
independent mechanism. These findings implicate LIN28B as a potential diagnostic
marker and/or therapeutic target in colon cancer.
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Experimental Procedures
Human tissue samples. Human colorectal cancer and adjacent normal colon
tissues were obtained from a collaborator (Dr. Naomoto) from the Department of
Surgery, Okayama University Medical School, Japan under Institutional Review Board
approval. Normal and tumor colon samples were stored in RNAlater (Qiagen, Valencia,
CA), at -80o C for later use. Tumor tissue was homogenized mechanically on ice and fine
particulates were collected via centrifugation at 4o C. RNA was isolated from
homogenized tissues using a mirVana RNA isolation kit RNA was isolated using
mirVana kit (Ambion, Austin, TX) and evaluated for integrity using a Bioanalyzer
(Agilent, Santa Clara, CA).

Biostatistical analysis of LIN28B and let-7 expression in human tumors. The
distributions of LIN28B, let-7a and let-7b fold change were right-skewed, hence a logtransformation was used to achieve approximate normality. Pearson correlation
coefficients were calculated to assess the strength of the linear association between
LIN28B vs. let-7a and let-7b. Statistical significance of comparisons between empty
vector and LIN28B transduced cells in migration, invasion, soft-agar assays were
determined by applying student’s t-test, where p<0.05 is considered statistically
significant. Pearson correlation coefficients were calculated to assess the strength of the
linear association between let-7a and let-7b, let-7 expression and tumor stage, and let-7
expression and survival.
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Mature MicroRNA detection. Total RNA was extracted from human tumors,
and genetically modified DLD1 and LoVo cells using the mirVana miRNA isolation kit
(Ambion, Austin, TX). A Taqman® MicroRNA Assay kit (Applied Biosystems,
Carlsbad, California) was employed to synthesize probe-specific cDNA for both let-7a
and let-7b using TaqMan® Universal PCR Master Mix, No AmpErase UNG (Applied
Biosystems, Carlsbad, CA) from 10ng of total RNA per sample. Levels of mature
microRNAs were measured via qPCR for the probe-specific cDNA using proprietary
primers (Applied Biosystems, Carlsbad, California) using ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Carlsbad, CA). PCR reactions were performed in
triplicate and standardized to levels of endogenous U47. Fold change for let-7a and let-7b
was determined by normalization to empty vector controls. Statistical significance of
comparisons between empty vector and let-7a-3-b was determined by applying student’s
t-test, with p<0.05 considered significant.

Detection of let-7a3-b pri-microRNA expression. Total RNA was extracted
from human tissues, transfected 293T, or transduced LIM 2405 and LoVo cells using the
mirVana miRNA isolation kit as described above. cDNA was synthesized from 5 μg total
RNA per sample using random hexamers and SuperScript II Reverse Transcriptase
(Invitrogen, Carlsbad, CA). Detection of let-7a3-b pri-microRNA intronic sequence was
achieved using PCR primers specific to the intronic sequence between let-7a-3 and let-7b
with the following sequences: ggggccgcctacactgagaag and ctggggcacgtgctgggaacct (in
triplicate). Fold change for let-7a-3-b was determined by using Image J analysis to
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quantify individual band intensities, followed by normalization to empty vector controls.
Statistical significance of comparisons between empty vector and let-7a-3-b was
determined by applying student’s t-test, with p<0.05 considered significant.

mRNA expression analysis via RT-qPCR. We used 3 μg isolated RNA for
cDNA synthesis with random oligomers. cDNA was synthesized from 5 μg total RNA
per sample using random hexamers and SuperScript II Reverse Transcriptase (Invitrogen,
Carlsbad, CA). Synthesized cDNA was then subjected to gene expression analysis for
LIN28B, PROM1, LGR5, DKK1, CCND2, and KIT probes, with β-actin as an endogenous
control (Ambion, Austin, TX). Real-time qPCR was conducted on the ABI Prism 7000
Sequence Detection System (Applied Biosystems, Carlsbad, CA) for each probe using
TaqMan® Universal PCR Master Mix (Applied Biosystems, Carlsbad, CA) as per the
manufacturer’s protocol. Fold change for each transcript was determined by
normalization to empty vector controls. The statistical significance of comparisons
between empty vector DLD1 and LoVo versus LIN28B-DLD1 and LIN28B-LoVo cells
was evaluated by applying student’s t-test, with p<0.05 considered significant.

Generation of constitutive LIN28B-expressing cell lines. Stable LIN28B
expression in IEC-6, DLD-1, and LoVo cells was achieved using MSCV-PIG-LIN28B
and empty vector control plasmids (gifts from Dr. Joshua Mendell). We transfected
Phoenix E (for rodent cell lines) and Phoenix A (human cell lines) cells with 30ug
plasmid DNA, and monitored transfection efficiency via detection of GFP expression by
light microscopy prior to virus collection. Viral containing supernatant was collected
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48hrs post-transfection, filtered through a 0.45μm membrane, immediately placed in
liquid nitrogen, and stored at -80o C for later use. IEC-6, DLD-1, and LoVo cells were
infected by applying virus-containing media plus polybrene (4 μg/ml) to cells, then
subjecting them to centrifugation at 1000g for 90 minutes. Inoculated cells were selected
in puromycin, expanded, and subsequently sorted for high GFP intensity and
corresponding LIN28B expression. Expanded cell cultures were maintained in DMEM
plus 10% FBS at 37 oC, 5% CO2.

Western blot analysis. Cells were lysed in RIPA buffer (5 ml 1M tris-Cl pH 7.4,
30 ml 5 M NaCl, 5 ml 20% NP-40, 5 ml 10 % sodium deoxycholate, 0.5 ml 20% SDS, 50
ml ddH2O) containing protease inhibitor cocktail (Roche Diagnostics, Manheim
Germany). Cellular debris was removed from lysates via centrifugation, and protein was
quantitated via the BCA Protein Assay Kit (Thermo Scientific, Rockford, IL). 20 μg total
protein was loaded onto 4-12% gradient gels for electrophoresis using Invitrogen western
blotting apparatus. Proteins were transferred to PVDF membranes as per Invitrogen
protocol, blocked in 5% non-fat milk in TBS-T, and blotted with Lin28b (Abcam,
Cambridge, MA), CDC34 (BD Transduction Laboratories, San Jose, California),
IGF2BP1 (Cell Signaling, Boston, MA), HMGA2 (Santa Cruz, Santa Cruz, California)
or β-actin (Sigma-Aldrich, St. Louis, MO) primary antibodies as per the manufacturer’s
protocol.

Migration and invasion assays. Invasion assay inserts (BD Biosciences, San
Jose, California) were rehydrated in tissue culture incubators for 2 hours with 500μl
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serum-free DMEM prior to use. Cells were trypsinized, washed with PBS and
resuspended in serum-free DMEM. 50,000 cells per well were plated in the upper
chamber of fluorescent transwell assay systems atop a migration insert (BD Biosciences,
San Jose, California) or a rehydrated invasion assay insert (BD Biosciences, San Jose,
California) in a final volume of 500μl. 750μl complete media (DMEM + 10% FBS) was
added to the lower chamber as a chemoattractant. The assay system was incubated at 37o
C, 5% CO2 overnight. Assay inserts were washed in PBS, then stained with calcein AM
(4 μg/ml). Fluorescence was detected at 580nm using a plate reader as per the
manufacturer’s protocol.

Soft agar assays. Empty vector and LIN28B-expressing cells were trypsinized
washed in PBS, and resuspended as a 2 ml single cell suspension containing: 50,000
cells/ml, 0.67% agarose, 10% FBS, and DMEM. The soft-agar suspensions were plated
in triplicate over 3 ml of solidified 1% agarose, 10% FBS, and DMEM in 6-well plates;
plated soft-agar/cell suspensions were permitted to solidify prior at room temperature
prior to incubation at 37 oC, 5% CO2. Colonies were photographed and counted at 6
weeks for IEC-6 cells, and 2 days for DLD-1 and LoVo cells. The statistical significance
of comparisons between empty vector LIN28B-expressing colonies was determined by
applying student’s t-test, with p<0.05 considered significant.

Let-7 expression in cell lines constitutively expressing LIN28B. We obtained a
let-7a lentiviral expression vector (gift from Jerome Torrisani), which was developed by
modifying pLenti6.2-GW (pBLOCK-iT) of the pLenti6/UbC/V5-DEST Gateway system
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(Invitrogen, Carsblad, CA). We transduced transduced LIN28B-LoVo and LIN28B-DLD1 cells using ViraPower (Invitrogen, Carsblad, CA) as per the manufacturer’s protocol.
GFP expression was monitored in transduced cells via light microscopy. GFP-positive
cells were subsequently selected in blasticidin prior to expansion.

Microarray analysis. We isolated RNA from LIN28B-DLD-1 and LIN28BLoVo cells using a mirVana kit (Ambion, Austin, TX). Isolated RNA was submitted to
The University of Pennsylvania Microarray Facility where quality control tests of the
submitted total RNA samples were performed via Agilent Bioanalyzer and Nanodrop
spectrophotometry. Subsequently, 100ng of total RNA was converted to first-strand
cDNA using reverse transcriptase primed by a poly(T) oligomer that incorporated a
synthetic RNA sequence. Second-strand cDNA synthesis was followed by ribo-SPIA
(Single Primer Isothermal Amplification, NuGEN Technologies Inc. San Carlo, CA) for
linear amplification of each transcript. The resulting cDNA was fragmented, assessed by
Bioanalyzer, and biotinylated. cDNA yields were added to Affymetrix hybridization
cocktails, heated at 99ºC for 2 min and hybridized for 16 h at 45ºC to Affymetrix Human
Gene 1.0 ST Array GeneChips (Affymetrix Inc., Santa Clara CA). The microarrays were
then washed at low (6X SSPE) and high (100mM MES, 0.1M NaCl) stringency and
stained with streptavidin-phycoerythrin. Fluorescence was amplified by adding
biotinylated anti-streptavidin and an additional aliquot of streptavidin-phycoerythrin
stain. A confocal scanner was used to collect fluorescence signal after excitation at 570
nm. All protocols were conducted as described in the NuGEN Ovation manual and the
Affymetrix GeneChip Expression Analysis Technical Manual.
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RNA Expression Bioinformatics. 3 independent biological replicates for each
condition were assayed on microarrays. Unsupervised hierarchical clustering by sample
was performed to confirm that replicates within each condition grouped with most
similarity, and to identify any outlier samples. Significance Analysis of Microarrays
(SAM v3.0, www-stat.stanford.edu/~tibs/SAM/) was used to generate lists of statistically
significant differentially expressed genes in pairwise comparisons of replicate averages
between conditions. 13,156 genes were observed to have higher RNA abundance in cells
with constitutive LIN28B expression versus control, and 15,771 genes were lower than in
control. Candidate genes were further filtered by fold-change (threshold = 5 fold) and the
resulting gene lists were tested for over-representation of Gene Ontology annotation
categories using the DAVID Bioinformatics Resources (david.abcc.ncifcrf.gov).
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Results
Mature let-7a and let-7b levels correlate with LIN28B expression in
colon tumors
We measured expression of let-7a and let-7b pri-microRNA via qPCR for of the
intronic portion of the let-7a-3-b cluster present on human chromosome 22q13.31 in 22
human colon adenocarcinomas paired with normal adjacent colonic mucosa. This
revealed that levels of mature let-7a and let-7b in tumors do not correlate with let-7a-3-b
cluster pri-microRNA expression (Table 1), alluding to a post-transcriptional mechanism
of let-7 down-regulation. Consequently, we measured via RT-qPCR mRNA expression of
the let-7 inhibitor, LIN28B (Figure 1). We then compared LIN28B expression to mature
let-7a and let-7b levels in the 22 human colon tumor samples paired with normal colon
(Figure 1; Table 1). We found that LIN28B expression negatively correlates with levels of
both mature let-7a (r=-0.47, p=0.0297) and let-7b (r=-0.41, p=0.0637) in colon tumors.

Constitutive LIN28B expression transforms immortalized colonic
epithelial cells, and promotes cellular migration and invasion in a let-7
dependent manner
In order to further elucidate the role of LIN28B in colon tumorigenesis, we
constitutively expressed human LIN28B in rat-derived immortalized colonic epithelial
(IEC-6) via retroviral transduction. Expression of ectopic LIN28B in IEC-6 cells reduces
levels of let-7a and let-7b isoforms by greater than 50% (Figure 2a-b). Surprisingly,
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although let-7 and its targets have known roles in cellular proliferation, proliferation rates
were not affected by constitutive LIN28B expression (data not shown). We then
examined the ability of LIN28B to promote migration and invasion via in vitro transwell
assays. We found that constitutive LIN28B expression promotes migration and invasion
of IEC-6 cells in culture (Figure 2c). Furthermore, IEC-6 cells, which at baseline do not
form colonies in soft agar, do so with constitutive LIN28B expression (Figure 2d). These
observations are also true for human colon cancer cell lines as well. Constitutive
expression of LIN28B in DLD-1 (data not shown) and LoVo colon cancer cells reduces
mature let-7a and let-7b levels (Figure 3a-b). Furthermore, LIN28B increases migration,
invasion, (Figure 3c) and soft agar colony formation in colon cancer cell lines (Figure
3d).
We next sought to determine whether LIN28B promotes tumorigenesis in a let-7
dependent manner. To that end, we co-expressed a decoy let-7a hairpin molecule (the
loop structure of this molecule is derived from mir-30, thereby eliminating the Lin28b
binding site) in cells constitutively expressing LIN28B. We succeeded in increasing
mature let-7a levels by more than 100% in these cells (Figure 4a). We then subjected
cells co-expressing LIN28B and let-7 to in vitro migration and invasion Boyden chamber
assays. We found that concomitant let-7 expression reduces cellular migration and
invasion in the presence of LIN28B overexpression, as determined via Boyden chamber
in vitro assays (Figure 4b-c). Notably, cells co-expressing LIN28B and let-7 exhibit more
migration and invasion than empty-vector controls (Figure 4b-c). This may indicate that
LIN28B’s effect on cellular migration and invasion is only partially dependent upon let-7
inhibition, portending potential let-7 independent functions of LIN28B.
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Microarray analysis reveals up-regulation of stem cell related genes,
canonical Wnt signaling: potential let-7 independent functions of
LIN28B
In order to elucidate underlying mechanisms of LIN28B-mediated tumorigenesis,
we subjected DLD-1 and LoVo colon cancer cell lines constitutively expressing LIN28B
to microarray analyses. We identified more than 184 transcripts (164 up-regulated; 20
down-regulated) that are more than 5-fold changed with constitutive LIN28B expression
(Table 2; Figure 5). Many genes up-regulated by LIN28B have reported roles in stem cell
biology. For example, KIT (also called CD117 or c-KIT), which has been used as a stem
cell marker and is crucial to maintenance of the hematopoeitic stem cell compartment
(Osawa et al, 1996; Ratajczak et al, 1992), is dramatically increased by LIN28B
expression (Figure 6b). In addition, we found the intestinal stem cell markers LGR5
(leucine-rich repeat-containing G-protein coupled receptor 5) and PROM1 (prominin 1)
to be increased with LIN28B expression. Of note, LGR5 is a transcriptional target of
canonical Wnt signaling (Barker et al, 2007; Van der Flier et al, 2007). Additional Wnt
targets including DKK1 (Dickkopf-related protein 1) (Chamorro et al, 2005; Niida et al,
2004) and CCND2 (cyclin D2) (Shtutman et al, 1999; Tetsu & McCormick, 1999) are upregulated by LIN28B overexpression in colonic epithelial cells as well (Figure 6a). These
results were verified by measuring transcript levels via RT-qPCR analysis and
correspond to increases in β-catenin levels observed in LIN28B-DLD-1 and LIN28BLoVo cells as well (Figure 6b).
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Regulation of gene expression is mediated by LIN28B in a let-7
dependent manner, but may also occur via let-7 independent
mechanisms
Since LIN28B represses let-7 biogenesis, one would expect high Lin28b levels to
relieve suppression of let-7 targets, resulting in their increased expression. Constitutive
expression of LIN28B in IEC-6, DLD-1 (data not shown), and LoVo colon cancer cells
reduces let-7 levels, resulting in increases in of let-7 targets, including IGF2BP1, CDC34,
and HMGA2 (Figure 7a). Therefore, constitutive LIN28B expression increases let-7
targets.
However, some genes that we have shown to be increased with constitutive
LIN28B expression, including LGR5, PROM1, KIT, and DKK1, are not predicted by
Target Scan and miRanda algorithms to be putative let-7 targets (Griffiths-Jones et al,
2006; Griffiths-Jones et al, 2008; Grimson et al, 2007; Lewis et al, 2005; mirBase, 2010;
TargetScan, 2010) (Figure 7b). This may indicate indirect regulation via let-7, or
potentially let-7 independent functions of LIN28B. We were particularly intrigued by
increased LGR5 and PROM1 transcript levels with LIN28B constitutive expression, as the
ability of Lin28b to promote expression of intestinal stem cell markers may indicate a
role for Lin28b in maintenance of the colonic stem cell compartment. LGR5 and PROM1
lack conventional let-7 binding sites in their 3’ UTR sequences (Griffiths-Jones et al,
2006; Griffiths-Jones et al, 2008; Grimson et al, 2007; Lewis et al, 2005; mirBase, 2010;
TargetScan, 2010). In order to determine whether these genes are regulated by LIN28B in
a let-7 dependent fashion, we measured LGR5 and PROM1 gene expression in cells coexpressing LIN28B and a let-7a decoy hairpin molecule which escapes Lin28b-mediated
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inhibition. We found that let-7 targets including HMGA2 and IGF2BP1 are reduced by
let-7 restoration; however, LGR5 and PROM1 remain elevated (Figure 7). This suggests
the possibility that regulation of these genes by LIN28B occurs via a let-7 independent
mechanism.
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Chapter 2 Tables & Figures
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Figure 1

Mature let-7a and let-7b, and LIN28B expression in colon tumors. RNA was isolated
from tumors paired with adjacent normal mucosa; mature let-7a and let-7b, and LIN28B
were detected via RT-qPCR. Relative expression of mature let-7a and let-7b, and LIN28B
in tumors was determined by normalization to adjacent colonic epithelium. (A) Levels of
mature let-7a and let-7b in 22 tumors compared to normal colonic epithelium. (B)
LIN28B expression in the same 22 tumors compared to normal colonic epithelium.
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Table 1

RNA expression ratio
(tumor:normal epithelium)

mature
let-7

let-7a-3-b cluster

>0.6
<0.6
Total

10
12
22

16
6
22

RNA expression ratio
(tumor:normal epithelium)

LIN28B

>2
0-2
Total

10
12
22

Decreased levels of mature let-7a and let-7b isoforms with concomitant LIN28B
overexpression in a subset of colon tumors. Summary of data presented in Figure 1.
RNA was isolated from tumors matched with adjacent normal colonic epithelium and
utilized for RT-qPCR analysis. We compared levels of mature let-7a and let-7b, with let7a-3-b cluster and LIN28B expression in 22 pairs of colon tumors and matched adjacent
normal colonic epithelium. let-7a-3-b expression levels do not correlate with mature let7a and let-7b levels. However, LIN28B expression negatively correlates with levels of
mature let-7a (r=-0.47, p=0.0297) and let-7b (r=-0.41, p=0.0637) in colon tumors.
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Figure 2

LIN28B expression promotes invasion, migration, and soft-agar colony formation in
IEC-6 cells. (A) Verification of exogenous LIN28B expression. Western blot for Lin28b
in IEC-6 cells transduced with MSCV-PIG-LIN28B retrovirus. (B) LIN28B reduces
mature let-7 isoforms. RT-qPCR for mature let-7 in transduced IEC-6 cells;
normalization to empty vector control. Decreased levels of mature let-7a and let-7b occur
in IEC-6 cells following LIN28B constitutive expression. (C) Lin28b increases migration
and invasion. Constitutive LIN28B expression in immortalized colonic epithelial (IEC-6)
cells promotes cell migration and invasion in Boyden chamber assays. (D) LIN28B
induces transformation. Photomicrograph (100x magnification) of soft-agar cultures from
empty vector and LIN28B-IEC6 cells with quantitation of colonies. LIN28B expression
confers the ability of immortalized IEC-6 cells to form colonies in soft-agar.
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Figure 3

LIN28B expression promotes invasion, migration, and soft-agar colony formation in
LoVo colon cancer cells. (A) Verification of exogenous LIN28B expression Western blot
for Lin28b in LoVo cells transduced with MSCV-PIG-LIN28B retrovirus. (B) LIN28B
reduces mature let-7 isoforms. Decreased mature let-7a and let-7b levels in LoVo cells
following constitutive LIN28B expression. (C) Lin28b increases migration and invasion.
LIN28B overexpression in LoVo cells increases cell migration and invasion. (D) LIN28B
promotes anchorage-independent growth. Constitutive LIN28B expression in LoVo colon
cancer cells increases soft-agar colony formation.

58

Figure 4

Restoration of mature let-7 attenuates LIN28B-mediated migration and invasion.
(A) Decoy let-7 hairpins escape LIN28B-mediated inhibition. RNA was isolated form
empty vector and LIN28B-LoVo cells transduced to express let-7a decoy hairpin
molecules and RT-qPCR performed to measure mature let-7a. Mature let-7a is increased
with decoy expression in empty vector and LIN28B-expressing cells. (B and C) LIN28Bmediated migration and invasion is let-7 dependent. In vitro migration and invasion
Boyden chamber assays for cells expressing empty vector, let-7, LIN28B, or coexpressing let-7 and LIN28B. Increased let-7 reduces migration and invasion of LoVo
cell constitutively expressing LIN28B.
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Table 2

Transcripts modulated by constitutive LIN28B expression in vitro. Microarray
analysis reveals 164 transcripts are up-regulated 5-fold or more, and 20 transcripts more
than 5-fold down-regulated by constitutive LIN28B expression in vitro.
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Figure 5

Constitutive LIN28B expression relieves let-7 target suppression. RNA was isolated
from empty vector and LIN28B-expressing DLD-1 and LoVo and RT-qPCR was done to
evaluate changes in let-7 targets: HMGA2, IGF2BP1, CCND2, and CDC34; target
transcript levels are normalized to empty vector cells. LIN28B overexpression in colon
cancer cells relieves let-7-mediated repression, thereby increasing target transcripts.
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Figure 6

Constitutive LIN28B expression up-regulates non-let-7 targets. (A) Transcripts upregulated by LIN28B that do not contain let-7 complimentary sites. RT-qPCR of RNA
isolated from empty vector and LIN28B-expressing DLD-1 and LoVo cells for LGR5,
PROM1, KIT, and DKK1; target transcript levels are normalized to empty vector cells.
LIN28B increases expression of transcripts that are not predicted let-7 targets in colon
cancer cells. (B) Western blot for β-catenin on protein extracts from empty vector and
LIN28B-expressing DLD-1 and LoVo cells. Total β-catenin is up-regulated with
constitutive LIN28B expression.
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Figure 7

LIN28B-mediated up-regulation of a subset of genes is let-7 dependent. (A)
Derepression of let-7 targets in cells that constitutively express LIN28B. Western blot for
let-7 targets CDC34, IGF2BP1 and HMGA2 in IEC-6, DLD-1, and LoVo cells that
constitutively express LIN28B. (B) let-7-dependent gene upregulation by LIN28B.
LIN28B Increased mature let-7 levels in LIN28B-LoVo cells restores repression of let-7
targets (C) LIN28B-mediated upregulation of non-let-7 targets is not ameliorated by let7 restoration. Upregulation of LGR5 and PROM1 in LIN28B-expressing cells is
maintained following let-7 restoration.
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Chapter 2 Summary
We found a correlation between increased LIN28B expression and decreased let7a and let-7b mature microRNAs in colon tumors, implicating a role for LIN28B in colon
cancer pathogenesis. In order to further elucidate this role, we constitutively expressed
LIN28B in immortalized colonic epithelial and human colon cancer cell lines. We
demonstrated that LIN28B promotes cellular migration, invasion, and soft-agar colony
formation in a manner partially dependent on let-7 inhibition. Microarray analyses
revealed several genes up-regulated with LIN28B constitutive expression including the
intestinal stem cell markers LGR5 and PROM1. These genes remain up-regulated
following let-7 restoration, suggesting a novel let-7 independent mechanism of regulation
by LIN28B. This work suggests LIN28B is a potential therapeutic and/or diagnostic
target. Therefore, further analysis of LIN28B function in vivo is indicated and thus
presented in Chapter 3.

64

Chapter 3

In vivo roles of LIN28B
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Background and Significance
Both LIN28 and LIN28B are implicated in multiple developmental processes,
largely as a consequence of their ability to repress let-7 biogenesis. In C. elegans, let-7 is
critical to the larval fate transition, and vulval specification (Johnson et al, 2005); Lin-28
mutants (where let-7 repression is dysfunctional) reiterate larval fates (Moss et al, 1997).
In human embryonic stem cells, let-7 levels increase during differentiation, partially as a
consequence of reduced LIN28 expression (Viswanathan et al, 2008). On a broader scale,
LIN28B mutations are associated with delayed onset of puberty in humans (Tommiska et
al, 2009), which may be modeled via transgenic expression of LIN28 in mice (Zhu et al).
Lin28 transgenic mice also display gut pathology (Zhu et al, 2010), further suggesting
involvement in intestinal development.
Functions of LIN28 have been described in both neurogliogenesis and skeletal
myogenesis (Balzer et al, 2010; Polesskaya et al, 2007). In neuronal cells, LIN28 is
down-regulated during differentiation; constitutive LIN28 expression in undifferentiated
cells blocks gliogenesis in favor of neurogenesis (Balzer et al, 2010; Polesskaya et al,
2007). Additionally, LIN28 is induced during myogenic differentiation and enforced
expression in myoblasts drives skeletal muscle myogenesis (Balzer et al, 2010;
Polesskaya et al, 2007). The functions of LIN28 in both neurogenesis and myogenesis are
dependent upon its ability to promote IGF2 (Insulin-like growth factor 2) mRNA
stabilization and transcription (Balzer et al, 2010; Polesskaya et al, 2007). IGF2 is also
upregulated during osteoblast differentiation of mesenchymal stromal cells (Hamidouche
et al, 2010). More importantly, loss of IGF2 imprinting results in a shift toward a less
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differentiated intestinal epithelium (Sakatani et al, 2005). As we have demonstrated,
expression of LIN28B relieves let-7-mediated repression of IGF2BP1 (Chapter 2), which
may increase translation of IGF2 by stabilizing its mRNA (Nielsen et al, 1999). The
ability of LIN28B to indirectly regulate IGF2 suggests roles for LIN28B in modulating
cellular differentiation programs.
Moreover, we previously showed that LIN28B expression results in up-regulation
of intestinal stem cell markers including PROM1 and LGR5, which may indicate specific
roles of LIN28B in intestinal stem cells. Within the intestine, expression of the cell
surface protein PROM1 is restricted to the crypt and adjacent epithelial cells (Snippert et
al, 2009), while expression of the orphan receptor LGR5 occurs exclusively in cycling
columnar cells within the crypt base (Barker et al, 2007). Since co-expression of LGR5
and PROM1 marks intestinal and colonic epithelial stem cells, the ability of LIN28B to
up-regulate them suggests roles for LIN28B in establishment and/or maintenance of
intestinal stem cells. Of note, LGR5 is an established target of the Wnt pathway (Barker
et al, 2007; Van der Flier et al, 2007), and constitutive LIN28B expression induces
additional targets of canonical Wnt signaling (Chapter 2). Since Wnt signaling is critical
to maintaining the intestinal stem cell niche (Kim et al, 2005; Reya & Clevers, 2005), the
ability of LIN28B to up-regulate Wnt targets may further indicate its involvement in
intestinal stem cell biology.

In order to elucidate further the functions of LIN28B, we evaluated the effect of
constitutive LIN28B expression in vivo by employing xenograft transplantation models.
We found that LIN28B overexpressing tumors display increased differentiation with
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evidence of enhanced glandular formation, in conjunction with increased LGR5 and
PROM1 expression. These findings suggest LIN28B might be involved in both cellular
re-programming and tumor progression. Of note, a subset of LIN28B-overexpressing
tumors display metastasis to the liver and lungs, whereas control cells do not.
Additionally, we find increased Lin28b expression (via immunohistochemistry)
correlates with reduced survival and increased probability of recurrence in patients with
colon cancer. This work supports roles for LIN28B in progression of colon cancer.
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Experimental Procedures
Xenograft injections. LIN28B was expressed constitutively in DLD-1 and LoVo
colon cancer cell lines via retroviral transduction as described in Chapter 2.
Immunocompromised nude mice were irradiated with 5 Gray 2-3 hours prior to injection.
Empty vector and LIN28B-expressing DLD-1 and LoVo cells were trypsinized and
washed in PBS and resuspended at a concentration of 2 x 107 cells/ml. 50 μl of cell
suspensions were mixed with 50 μl of BD Matrigel™ Basement Membrane Matrix (BD
Biosciences, Franklin Lakes, NJ) to achieve a volume of 100 μl containing 1 x 106 cells
per injection. Cells were injected subcutaneously into the rear flanks of nude, athymic,
RAG-1–/– mice sedated with ketamine (100 mg/kg) and xylazine (10 mg/kg. Following
injection, mice were monitored periodically and sacrificed 6 weeks post-injection. All
mice were cared for in accordance with University Laboratory Animal Resources
requirements.

Detection of GFP fluorescence in live mice by image analysis. We anesthetized
xenografted nude mice with ketamine (100 mg/kg) and xylazine (10 mg/kg) and
measured fluorescence intensity using a small animal imaging system (Kodak, Rochester,
NY). Net tumor intensity was calculated over a fixed region of interest (ROI) that
encompasses the dimensions of the largest tumor. Statistical significance of comparisons
between empty vector and LIN28B tumors was determined by applying student’s t-test,
where p<0.05 is statistically significant.
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Histopathological analysis of primary tumors and metastases. Moderate
differentiation, and poor differentiation were scored as a percentage of viable tumor
epithelium on hematoxylin and eosin stained xenograft section. Mucin production in
areas of poor and moderate differentiation was determined via mucicarmine staining;
scored as a percentage of viable tumor epithelium. Statistical significance of comparisons
between empty vector and LIN28B tumors was determined by applying student’s t-test,
where p<0.05 is considered statistically significant. Metastases observed via gross and
histopathologicial examinations were verified in conjunction with a board-certified
pathologist, and by immunohistochemical detection of green fluorescent protein (GFP)
expressed from the MSCV-PIG vector.

Gene expression analysis of xenograft tumors. Mice were euthanized in
accordance with ULAR (University Laboratory Animal Resources) standards prior to
excision of xenograft tumors. Extraneous tissues were dissected away and discarded,
tumors were then immediately placed into RNAlater (Qiagen, Valencia, CA) and
maintained on ice until storage at -80o C. Tumor tissue was homogenized mechanically in
RNAlater (Qiagen, Valencia, CA), and homogenized particulates were collected via
centrifugation at 4o C. RNA was isolated from homogenized tissues using a mirVana
RNA isolation kit (Ambion, Austin, TX). cDNA was synthesized from 3 μg isolated
RNA per sample using random oligomers and SuperScript II Reverse Transcriptase
(Invitrogen, Carlsbad, CA). Synthesized cDNA was then subjected to gene expression
analysis via real-time qPCR using the ABI Prism 7000 Sequence Detection System
(Applied Biosystems, Carlsbad, CA). Transcripts were amplified and detected using
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PROM1 and LGR5 specific probes, with β-actin serving as an endogenous control
(Ambion, Austin, TX). Fold change for each transcript was determined by normalization
to empty vector controls. The statistical significance of comparisons between empty
vector DLD1 and LoVo versus LIN28B-DLD1 and LIN28B-LoVo cells was evaluated by
applying student’s t-test, with p<0.05 considered significant.

Microarray analysis. We isolated RNA using a mirVana kit (Ambion, Austin,
TX) from excised empty vector tumors, LIN28B-LoVo tumors, and LIN28B-LoVo
mesenteric metastases. We then submitted triplicate RNA isolates to the Penn Microarray
Facility. Quality control tests of the submitted total RNA samples were performed using
Agilent Bioanalyzer and Nanodrop spectrophotometry. 100ng of total RNA was then
converted to first-strand cDNA using reverse transcriptase primed by a poly(T) oligomer
that incorporated a synthetic RNA sequence. Second-strand cDNA synthesis was
followed by ribo-SPIA (Single Primer Isothermal Amplification, NuGEN Technologies
Inc. San Carlo, CA) for linear amplification of each transcript. The resulting cDNA was
fragmented, assessed by Bioanalyzer, and biotinylated. cDNA yields were added to
Affymetrix hybridization cocktails, heated at 99ºC for 2 min and hybridized for 16 h at
45ºC to Affymetrix Human Gene 1.0 ST Array GeneChips (Affymetrix Inc., Santa Clara
CA). The microarrays were then washed at low (6X SSPE) and high (100mM MES,
0.1M NaCl) stringency and stained with streptavidin-phycoerythrin. Fluorescence was
amplified by adding biotinylated anti-streptavidin and an additional aliquot of
streptavidin-phycoerythrin stain. A confocal scanner was used to collect fluorescence
signal after excitation at 570 nm. All protocols were conducted as described in the
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NuGEN Ovation manual and the Affymetrix GeneChip Expression Analysis Technical
Manual.

RNA Expression Bioinformatics. 3 independent biological replicates for each
condition were assayed on microarrays. Unsupervised hierarchical clustering by sample
was performed to confirm that replicates within each condition grouped with most
similarity, and to identify any outlier samples. Significance Analysis of Microarrays
(SAM v3.0, www-stat.stanford.edu/~tibs/SAM/) was used to generate lists of statistically
significant differentially expressed genes in pairwise comparisons of replicate averages
between conditions. 11,242 genes were observed to have higher RNA abundance in
LIN28B metastases versus control, and 17,579 genes were lower than in control.
Candidate genes were further filtered by fold-change (threshold = 4 fold) and the
resulting gene lists were tested for over-representation of Gene Ontology annotation
categories using the DAVID Bioinformatics Resources (david.abcc.ncifcrf.gov).

Tumor Tissue Microarray Analysis. Samples of colorectal adenocarcinomas
tumors and adjacent normal colonic mucosa were obtained from patients diagnosed and
staged with colorectal adenocarcinomas under Institutional Review Board approval. Two
cores of normal mucosa and two cores of tumor tissue for each represented individual
were paraffin-embedded in ordered microarrays (gift from Toni Castells and Miriam
Cuatrecasas, University of Barcelona). Tumor microarrays were sectioned in preparation
for immunohistochemical staining.
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Immunohistochemistry. Paraffin-embedded tissue microarrays and xenograft
tumors were incubated at 60o C prior to de-waxing and rehydration. Tissues were
incubated in xylene (5 min. x 2), followed by incubations in incremental dilutions of
ethanol: 100% (2 min. x 2), 95% (1 min.), 80% (1 min.), 70% (1 min.), ddH2O (1 min.).
We then performed antigen retrieval on sections by placing them in 10 μM citric acid (pH
6) and microwaving for 15 minutes. Samples were allowed to cool for 15 minutes prior to
rinsing. Endogenous peroxidases were quenched in 15 ml hydrogen peroxide and 185 ml
of water. Tissues were rinsed in water and washed with PBS prior to treatment with
Avidin D and Biotin using Vectastain (Vector Labs, Burlingame, CA). Samples were
washed again with PBS prior to treatment with Starting Block (Thermo Scientific,
Rockford, IL) for 10 minutes. Tissues were incubated in Lin28b (1:200; Cell Signaling,
Boston, MA) Lgr5 (1:250; Lifespan Biosciences, Seattle, WA) or prom1 (1:100 Cell
Signaling, Boston, MA) primary antibodies diluted in PBT (10X PBS, 10% BSA, 10%
Triton X-100 in ddH2O) at 4o C overnight. The following day, samples were washed with
PBS, and treated with ABC Peroxidase Staining Kit (Pierce, Rockford IL) as per the
manufacturer’s protocol. For detection, DAB reagent was prepared from a DAB
Peroxidase Detection Kit (Vector Labs, Burlingame, CA) during the last PBS washes by
adding 1 drop of buffer, 2 drops of DAB solution, and 1 drop of peroxide solution and
applied to sections. We monitored color development using a light microscope in order to
determine an appropriate incubation period for each primary antibody tested. The
development process was terminated removing DAB (into a chemical hazard waste
container) and rinsing the sections with ddH2O for 1 min prior to counterstaining with
hematoxylin.
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Tumor tissue microarray biostatistical analysis. Each core of normal and
tumor mucosa stained for Lin28b via immunohistochemistry was scored according to
intensity (collaboration with Toni Castells and Miriam Cuatrecasas, University of
Barcelona). 1 was used to signify low Lin28b intensity, 2 for intermediate intensity, and 3
for high. Logrank tests (Mantel–Cox and Breslow) were performed to compare survival
and recurrence distributions of intensity groups (1-2 vs 3). Correlation of staining
intensity with survival and recurrence was determined via Chi-square analysis; 95%
confidence interval calculated for confirmation of statistical significance
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Results

LIN28B tumors exhibit moderate differentiation with glandular
formation, in conjunction with increased intestinal stem cell marker
expression
In order to determine in vivo roles of LIN28B in tumorigenesis, we xenografted
our previously described LIN28B-DLD-1 and LIN28B-LoVo cells (Chapter 2)
subcutaneously into the rear flanks of nude mice (1 million cells per injection). We
injected a total of five cohorts and monitored tumor development in each over the course
of six weeks. A total of 83 mice (41 in the empty vector; 42 LIN28B tumors) were
evaluated in this study (Table 1).
Prior to euthanizing mice and performing necropsies, we approximated tumor size
for each cohort at two week intervals. We determined fluorescent intensity of tumors as a
quantitative measure of green fluorescent protein expression, which is exogenously
expressed from the MSCV-PIG retroviral vector. At each interval, we found LIN28B
tumors emit less fluorescence than empty vector controls (Figure 1a). This observation
corresponds to a smaller mass of LIN28B xenografts as determined by weighing extracted
tumors post-sacrifice (Figure 1b).
We confirmed LIN28B overexpression in smaller tumors by
immunohistochemistry (Figure 2a-b), and established that mature let-7 microRNA levels
are decreased in xenografts where LIN28B is constitutively expressed (Figure 3).
Interestingly, Ki-67 staining is comparable between empty vector and LIN28B tumors,
suggesting the reduction in tumor size observed for LIN28B tumors did not occur as a
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consequence of a cellular proliferation defect (data not shown). Similarly,
immunostaining for caspase-3 did not reveal differences between empty vector and
LIN28B tumors, suggesting the smaller tumor size is not a result of increased apoptosis
(data not shown).
Yet, the histological architecture of LIN28B tumors is somewhat surprising in that
they exhibit fewer necrotic areas, moderate differentiation, glandular formation, and
increased mucin production (Figure 2d). This stands in contrast to empty vector tumors
which are poorly differentiated, have large necrotic foci, and rarely exhibit mucinous
gland-like structure (Figure 2c; Figure 3a-d). Immunoassaying for the colon cancer
marker Cdx2 did not reveal differences between empty vector and LIN28B-expressing
tumors (data not shown). Yet notably, the intestinal stem cell markers LGR5 and PROM1
are also up-regulated with in vivo constitutive LIN28B expression (Figure 4). These
findings suggest roles for LIN28B in regulating differentiation and/or modulating cellular
re-programming.

Constitutive LIN28B expression promotes metastasis of xenograft
tumors
Although LIN28B xenograft tumors are smaller and appear more differentiated
than their empty vector counterparts (Figure 5), they are capable of metastasizing to
multiple organ sites (Figure 6). We observed liver and lung metastases in mice bearing
tumors with constitutive LIN28B expression, at times, upon gross examination (Figure
6).We also noted metastases to perisplenic adipose tissue, lymph nodes, and mesentery.
These metastases were confirmed with a histopathologist and via immunohistochemical
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detection of green fluorescent protein expression, which is unique to xenografted tissues
(Figure 6c-d). Of note, we did not observe metastases in any mice of the empty vector
control group. Overall, we identified metastases in 10% of the LIN28B xenografts (Table
2). Thus, constitutive expression LIN28B confers metastatic ability in at least a subset of
tumors (Fisher’s exact one-tailed probability = 0.061).

The gene expression profile induced by constitutive LIN28B expression
in vitro overlaps with the profile in vivo
We sought to elucidate potential mechanisms whereby LIN28B promotes metastasis by
comparing the gene expression profile of LIN28B metastases to primary tumors.
Accordingly, we performed microarray analysis on total RNA isolated from empty vector
tumors, LIN28B-LoVo tumors, and LIN28B-LoVo metastases. We identified more than
22 genes that are more than 4-fold up-regulated, and 57 genes that are more than 4-fold
down-regulated by constitutive LIN28B expression in vivo (Table 3). Many genes that are
up-regulated with constitutive LIN28B expression in vitro are also increased with
constitutive LIN28B expression in vivo, including the stem cell markers LGR5, PROM1,
and the let-7 targets HMGA2 (High-mobility group AT-hook 2) and IGF2BP1 (Insulinlike growth factor 2 mRNA-binding protein 1); these results were verified by RT-qPCR
analysis (data not shown). Overall, the expression profile of empty vector tumors varies
dramatically from that of LIN28B tumors. Notably, the expression profile of LIN28B
metastases also differs from that of LIN28B primary tumors. Some genes that are
specifically modulated in LIN28B metastases versus primary tumors, including TNS4
(Tensin 4), CHI3L1 (Chitinase 3-like-1), and KLK6 (Kallikrein 6), have described roles
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in migration, invasion, and metastasis, and are therefore prime candidates for future
studies (Bockholt & Burridge, 1993; Ghosh et al, 2004; Mizoguchi, 2006).

LIN28B overexpression correlates with reduced patient survivability
Our work suggests that LIN28B may serve as a prognostic factor in patients with
colon cancer. To that end, we evaluated Lin28b protein levels in colon cancers and
adjacent normal mucosa resected from patients receiving adjuvant 5-fluorouracil (Figure
8a). We performed immunohistochemistry for Lin28b; staining was scored according to
intensity by a pathologist. We then performed logrank tests (Mantel–Cox and Breslow) to
compare survival and recurrence distributions of intensity groups. We found that low
intensity of Lin28b staining in stage I and II colon tumors correlates with higher patient
survival (Mantel-Cox p value = 0.046; Breslow, p value = 0.013), and a lower probability
of tumor recurrence (Mantel-Cox p value = 0.036; Breslow p value = 0.108) (Figure 8bc). This indicates a worse prognosis for patients with early stage tumors that exhibit high
intensity Lin28b staining.

79

Chapter 3 Tables & Figures
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Table 1

Vector

LIN28B

Total

DLD-1

18

19

37

LoVo

23

23

46

41

42
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Xenograft tumors evaluated in mice. Vector-DLD-1, LIN28B-DLD-1, vector-LoVo, or
LIN28B-LoVo cells were injected subcutaneously in to the rear flanks of nude mice. A
total of 41 empty vector and 42 LIN28B-expressing tumors were evaluated.
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Figure 1

Smaller size of LIN28B tumors. (A) LIN28B tumors emit less fluorescence than
controls. GFP intensity of xenograft tumors was assessed at bi-weekly intervals; at each
interval, fluorescence intensity for LIN28B tumors was less than controls. Representative
2 and 4 week analyses of a single cohort injected with vector-LoVo or LIN28B-LoVo
cells. (B) LIN28B tumors are smaller than controls. Tumor weight 6 weeks postinjection and extraction.
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Figure 2

Histopathological examination of empty vector and LIN28B-expressing primary
tumors. (A and B) Confirmation of LIN28B overexpression in tumors.
Immumnohistochemical detection of Lin28b in vector-LoVo and LIN28B-LoVo
xenografts; representative of 83 tumors tested (200x magnification). (C-F) Hematoxylin
and eosin staining of xenograft tumors. LIN28B tumors exhibit fewer necrotic areas,
moderate differentiation, glandular formation, and increased mucin production. (100x
magnification in C and D, 200x in E and F).
83

Figure 3

LIN28B represses let-7 in xenograft tumors. Empty vector and LIN28B-LoVo tumors
were homogenized and RNA isolated for RT-qPCR to evaluate levels of mature let-7a
and let-7b. Constitutive LIN28B expression suppresses let-7 in vivo.
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Figure 4

LGR5 and PROM1 are up-regulated by constitutive LIN28B expression in vivo.
Empty vector and LIN28B-LoVo tumors were homogenized and RNA isolated for RTqPCR to evaluate LGR5 and PROM.
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Figure 5

Differentiation and mucin production in LIN28B tumors. (A) Poor differentiation in
xenograft tumors. Area exhibiting poor differentiation scored as a percentage of viable
tumors. LIN28B-expressing tumors exhibit fewer areas of poor differentiation. (B)
Moderate differentiation in xenograft tumors. Area exhibiting moderate differentiation
scored as a percentage of viable tumors. Differentiation is increased in LIN28Bexpressing tumors. (C) Mucin positivity in poorly differentiated tumor areas. Mucin was
detected via mucicarmine staining. Mucin positivity in poorly differentiated scored as a
percentage of viable tumor. (D) Mucin positivity in moderately differentiated tumor
areas. Mucin positivity in poorly differentiated scored as a percentage of viable tumor.
Differentiation is increased in LIN28B-expressing tumors. Mucin production is increased
in LIN28B-expressing tumors.
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Figure 6

A subset of LIN28B-expressing primary tumors metastasize. (A) Lung metastasis
from a LIN28B-DLD1 subcutaneous xenograft. Hematoxylin and eosin staining. (B)
Liver metastasis from a LIN28B-LoVo subcutaneous xenograft. Hematoxylin and eosin
staining; note invasion of metastasis into normal liver (C and D) Metastases are GFPpositive. Immunohistochemistry for GFP expressed from MSCV-PIG retroviral vector
confirms that these tissue originated from xenograft injections. (E) Metastases visible
upon gross examination. Arrows indicate liver and mesenteric metastases from LIN28BLoVo tumors (magnification = 100x in panels A and B; 200x in panels C and D).
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Table 2
Vector

LIN28B

-met

41

38

+met

0

4*

Total

41

42
*p = 0.061

Metastasis in xenografted mice. Of the 83 mice we evaluated, we observed metastases
in 4 animals - 10% of xenografted mice (Table 2). Thus, constitutive expression LIN28B
confers metastatic ability in at least a subset of tumors (Fisher’s exact one-tailed
probability = 0.061).
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Table 3

Transcripts modulated by constitutive LIN28B expression in vivo. Microarray
analysis reveals 19 transcripts up-regulated 4-fold or more, and 56 transcripts more than
5-fold down-regulated by constitutive LIN28B expression in vitro.
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Figure 7

LIN28B overexpression in tumors correlates with reduced survival and increased
probability of tumor recurrence. (A -D) Representative H & E and IHC for Lin28b in
normal colon and colon tumor mucosa from tumor microarrays. Lin28b staining is
intense in a subset of colon tumors. (E) Lin28b expression and survival. High Lin28b
staining intensity in stage I and II tumors correlates with reduced patient survival. (F)
Lin28b and recurrence. High Lin28b in stage I and II tumors correlates with increased
probability of tumor recurrence.
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Chapter 3 Summary
We analyzed in vivo roles of LIN28B in tumorigenesis by xenografting
retrovirally transduced colon cancer cells into nude mice. Tumors that constitutively
express LIN28B display increased differentiation with glandular formation, in
conjunction with increased LGR5 and PROM1 expression. Moreover, LIN28B tumors
exhibit metastasis, whereas empty vector tumors do not. This finding supports a role for
LIN28B in progression to metastatic colon cancer. Furthermore, increased Lin28b
staining intensity in early stage colon cancers correlates with reduced patient survival.
Together, our findings in nude mice and human colon tumors highlight the potential
diagnostic and/or therapeutic utility of targeting LIN28B in colon cancer.
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Discussion and Future Directions
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Summary of findings
We hypothesized that LIN28B promotes colon tumorigenesis via suppression of
let-7 in the colon. In pursuing this hypothesis, we demonstrated initially a reduction in
mature let-7a and let-7b levels in colon tumors when compared to matched adjacent
normal colonic epithelium. While let-7 pri-microRNA expression does not vary greatly,
reduced let-7 levels in tumors does correlate with increased LIN28B expression.
Furthermore, LIN28B overexpression correlates with reduced survival and increased
tumor recurrence in colon cancer patients.
We demonstrated potential tumor suppressive functions of let-7a and let-7b in
colon cancer cell lines via constitutive expression of a let-7a-3-b pri-microRNA.
Increased let-7a and let-7b represses let-7 targets, while inhibiting cell migration and
invasion. Importantly, let-7 is regulated post-transcriptionally by Lin28b, an RNAbinding protein. Constitutive LIN28B expression in immortalized colonic epithelial and
colon cancer cells promotes cellular migration, invasion, transformation, and results in
de-repression of let-7 targets. Restoration of let-7 levels does not ameliorate all LIN28B
effects, suggesting the possibility of let-7 independent functions of LIN28B.
Constitutive LIN28B expression modulates many gene transcripts as revealed by
microarray analyses. These genes include the intestinal stem cell markers LGR5 and
PROM1, which are not predicted let-7 targets, and remain up-regulated following let-7
restoration. The ability of LIN28B to up-regulate LGR5 and PROM1 suggests possible
functions of LIN28B in cellular re-programming, further supported by the observation
that LIN28B promotes differentiation in vivo. Additionally, we observed metastases in a
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subset of LIN28B-expressing primary tumors, suggesting a role for LIN28B in
progression to metastatic colon cancer.

Implications of tumor-suppressive functions of let-7 in colon cancer
let-7 microRNAs exhibit tumor suppressive functions in a variety of cancers
(Akao et al, 2006; Esquela-Kerscher & Slack, 2006; Kumar et al, 2008; Shell et al, 2007;
Takamizawa et al, 2004; Viswanathan et al, 2008; Yu et al, 2007a), which may reflect the
high degree of sequence homology between the 12 let-7 isoforms (Vella & Slack, 2005).
Although we have demonstrated reduced levels of mature let-7a and let-7b in colon
tumors, we did not evaluate the remaining let-7 isoforms, which may compensate for the
reduction of let-7a and let-7b. However, we did show previously that let-7a and let-7b are
the major let-7 isoforms expressed in the human colon. Furthermore, we demonstrated a
statistically significant inverse correlation between LIN28B overexpression and reduced
let-7a and let-7b levels in colon tumors. Constitutive LIN28B expression in colonic
epithelial cells results in down-regulation of all let-7 isoforms, and, thus it is unlikely that
Lin28b-mediated reductions in let-7a and let-7b in colon tumors are compensated by
other let-7 microRNAs.
Additional roles of let-7a and let-7b in colon tumorigenesis remain to be
determined. Although let-7 down-regulation occurs in two-thirds of colon tumors,
LIN28B overexpression does not occur frequently enough to account for let-7 repression
in all these tumors. While variations in let-7 pri-microRNA expression may account for
some changes in mature let-7 levels, it is possible that other post-transcriptional
mechanisms of let-7 repression account for these differences. For example, LIN28
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overexpression may occur in a subset of tumors where let-7 repression occurs, novel
repressors of let-7 biogenesis may exist, or perhaps other proteins that effect let-7
microRNA stability are reduced in these cells.

The functional roles of let-7 in vivo
Genetically engineered cell lines and/or mice in which let-7 expression may be
temporally and/or spatially controlled would be excellent tools for assessing roles of let-7
microRNAs in colon tumorigenesis. Since let-7a and let-7b are the major let-7 isoforms
expressed in the human colon, the let-7a-3-b bicistronic cluster on chromosome 22q13.31
is a prime candidate for genetic manipulation. In that context, one might consider a
conditional knock-out of the let-7a-3-b locus (let-7c-2-b in mice), which may be
developed by inserting flanking loxP sites around the microRNA cluster (this is being
done in the lab currently). Similarly, a transgene driving expression of anti-sense RNAs
that bind to and inhibit let-7 isoforms may be employed. While disrupting let-7 function
alone may not initiate transformation of colonic epithelial cells, let-7a-3-b conditional
knockouts could be combined with existing mouse models (e.g. APC mutation), allowing
one to evaluate the roles of let-7 microRNAs in accelerating colon tumorigenesis.
Alternatively, one might consider transgenic overexpression of let-7 in mice,
where the ability of let-7 to inhibit colon tumorigenesis in vivo may be evaluated. One
might predict that let-7 overexpression would delay tumor formation in the colon or
potentially reverse tumor development as observed previously with introduction of let-7
into lung adenocarcinomas (Esquela-Kerscher et al, 2008; Trang et al, 2010). The ability
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of let-7 to inhibit the development of colon tumors could be evaluated by breeding let-7
transgenic mice with established models of colon cancer.

Potential roles of let-7 in colon differentiation
Given that let-7 coordinates differentiation programs (Johnson et al, 2007; Shell
et al, 2007; Tsonis et al, 2007; Yu et al, 2007a), resolving the functions of let-7
microRNAs in colonic development may aid in elucidating the roles LIN28B in cellular
re-programming and differentiation in the colon. One might predict that let-7
overexpression would promote intestinal differentiation, while inhibition of let-7
microRNAs might delay or inhibit differentiation. Genetic manipulations that permit
temporal and/or spatial control of let-7 expression in mice or epithelial cell lines would
be helpful. Colonic organogenesis and epithelial differentiation may be evaluated in let-7
conditional knockout and/or transgenic mice. Alternatively, the functions of let-7 in
colonic differentiation may be evaluated in vitro by utilizing cell lines where let-7
expression is inducible. Here, models of intestinal differentiation, such as in CaCo-2 or
fetal colonic epithelial cells grown in standard two-dimensional or organotypic culture,
may be employed. Both cell types spontaneously differentiate in culture to what closely
recapitulates the mature colonic epithelium (Kalabis et al, 2008; Kalabis et al, 2003;
Sambuy et al, 2005). Thus, overexpression or inhibition of let-7 in these cells may serve
as useful tools for evaluating functions of let-7 in intestinal differentiation. One might
predict that let-7 overexpression would shorten the time required for either cell type to
spontaneously differentiate, which may be assessed by evaluating markers of enterocyte
differentiation, including villin, carbonic anhydrase, and intestinal alkaline phosphatase
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(Bekku et al, 1998; Dahlqvist & Lindberg, 1965; Maunoury et al, 1992), as well as
microvillus brush border development via electron microscopy.

Elucidating let-7 independent functions of LIN28B
Manipulating let-7 expression via overexpression or inhibition may be
implemented as a means of determining let-7 independent functions of LIN28B as well.
For example, we have identified a number of genes that are modulated with constitutive
LIN28B expression. Still, it remains to be determined whether LIN28B affects these genes
in a let-7 dependent manner. Each gene of interest may be evaluated in the context of
constitutive LIN28B expression coupled with let-7 restoration, as we have done for
HMGA2, IGF2BP1, LGR5 and PROM1. This would aid in determining whether these
genes are regulated by Lin28b in a let-7 dependent or independent fashion, whether
directly or indirectly. Alternatively, a comparative bioinformatics approach which
compares our microarray results with predicted let-7 targets may be undertaken. Such a
bioinformatics study may offer insights to additional let-7 independent functions of
LIN28B, and elucidate whether LIN28B functions primarily as an inhibitor of let-7, or if
let-7 repression occurs as one of several LIN28B functions (as our microarray results
suggest).
Mutations that specifically ameliorate the ability of LIN28B to inhibit let-7 would
be useful also in further elucidating the mechanisms of LIN28B’s functions. This may be
achieved by introducing point mutations into the cold-shock domain of LIN28B, which
has been utilized for evaluating let-7 independent functions of LIN28 (Balzer et al, 2010).
However, cold-shock domain mutations may disrupt all RNA-binding activities of
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LIN28B, thereby precluding assessment of specific let-7 independent functions. A more
specific approach involves first determining the specific domains and/or amino acid
residues of LIN28B essential for repression of let-7 biogenesis, which may be
accomplished by introducing mutations and/or deletions into LIN28B systematically, then
targeting these domains or amino acids exclusively. Cells expressing the resulting
LIN28B mutant may be evaluated in migration, invasion, xenograft assays, and
microarray studies. Targeting the specific domains of LIN28B required for let-7 inhibition
in genetically engineered mice would further aid in determining whether the ability to
repress let-7 is essential to LIN28B’s roles in organ development and tumorigenesis.

LIN28B overexpression in colon cancer
We have demonstrated increased LIN28B expression in colon tumors, which
likely occurs as a result of increased LIN28B transcriptional activity mediated by c-myc.
Since c-myc is a transcriptional target of canonical Wnt signaling, it is possible that
LIN28B is up-regulated in colon tumors as a consequence of APC mutation (or other
changes that deregulate Wnt signaling), which occurs in virtually all colon tumors. We
may conclusively determine whether increased c-myc correlates with high Lin28b in
colon tumors by performing immunohistochemistry for c-myc in our tissue microarrays.
Alternatively, up-regulation of LIN28B in colon tumors may occur as a result of
increased mRNA stabilization. Interestingly, this may occur as a result of decreased let-7
in colon tumors, as LIN28B is also a predicted let-7 target (Griffiths-Jones et al, 2006;
Griffiths-Jones et al, 2008; Grimson et al, 2007; Lewis et al, 2005; mirBase, 2010;
TargetScan, 2010). The ability of let-7 and LIN28B to regulate one another other likely
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represents a feedback loop that allows the cell to tightly regulate levels of each, further
highlighting their importance in cellular function. Of note, SNPs that disrupt let-7 binding
occur within the 3’ UTR of the established let-7 target KRAS (Nelson et al, 2010). The
presence of these SNPs increases risk for non-small cell lung cancer by providing an
alternative mechanism for up-regulating oncogenic KRAS in tumors (Chin et al, 2008).
Accordingly, SNPs may exist in the 3’ UTR of LIN28B, which may account for increases
in LIN28B transcripts observed in tumors. Sequencing the 3’ UTR of both LIN28B loci
present in patients with colon cancers may offer insight into this possibility.

The ability of c-myc to transactivate LIN28 has not been described, and may
account for differential implications of LIN28 and LIN28B in colon cancer. However, it is
important to note that distinct functions have not been described for either homolog, and
it is possible that the two are completely redundant. Perhaps there are critical differences
between the expression patterns of LIN28 and LIN28B in tissues, which may be
determined by conducting in situ hybridization and comparing the mRNA expression
profiles of each homolog to one another. It is especially important to identify distinct
functions of these homologs if LIN28B is to be targeted therapeutically in colon cancer,
as inadvertent inhibition of LIN28 may result in intolerable toxicities. Also of note, if
LIN28 and LIN28B function redundantly in colon tumorigenesis, LIN28 may be upregulated in tumors where LIN28B is targeted as a means of compensation. Accordingly,
both the distinct and overlapping functions of LIN28 and LIN28B are important
considerations when designing small-molecule inhibitors of either.
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LIN28B in transformation, cell migration, invasion, and metastasis
We found that constitutive LIN28B expression promotes transformation, cell
migration, and invasion in vitro, and causes a subset of xenograft tumors to metastasize.
This coupled with the inverse correlation between LIN28B expression and patient
survivability suggests roles for LIN28B in progression of early stage polyps to invasive
and/or metastatic colon carcinoma. The vast majority of colon cancer deaths occur as a
result of invasive or metastatic disease (ACS, 2010). Thus, unraveling the mechanisms
underlying LIN28B’s ability to foster transformation, migration, invasion, and metastasis
is of interest, as this may reveal novel therapeutic targets for colon cancer.
Whether LIN28B is required for any of these cellular processes could be
determined via deletion or inhibition of LIN28B expression. We attempted to knockdown LIN28B in colon cancer cell lines using RNA interference without success. This is
perhaps attributable to low LIN28B transcript levels that accompany the presence of
detectable Lin28b protein in DLD-1 and LoVo cells (data not shown). However, the
CaCo-2 cell line exhibits high levels of LIN28B mRNA (data not shown). Thus, one
might consider expanding this work by inhibiting LIN28B in CaCo-2 cells through the
use of siRNAs. An unfortunate drawback to this method is that CaCo-2 cells are
incapable of migration and invasion in Boyden chamber assays (data not shown), and
thus may not undergo metastasis when xenografted. Still, a requirement for LIN28B in
cellular transformation may be elucidated by performing soft-agar colony formation
assays with CaCo-2 cells. Furthermore, an siRNA approach in CaCo-2 cells may aid in
determining additional mRNA transcripts that LIN28B modulates.
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Clues to the how LIN28B overexpression might foster transformation, migration,
invasion, and metastasis may be obtained from mining our microarray data. The most
provocative genes include those which are specifically modulated in LIN28B metastases
as compared to LIN28B-expressing primary tumors; as a transcript that is induced in
metastatic tumors may constitute a potential mechanism by which metastasis occurs. We
explored our microarray data comparing empty vector, LIN28B-expressing primary
tumors and LIN28B metastases for genes involved in cell migration, invasion, and
metastasis; recognizing that cell migration and invasion are distinct processes from
metastasis, yet regularly associated with it.
Three genes that are more than 4-fold changed in metastases as compared to
primary tumors are particularly interesting: TNS4 (Tensin 4), CHI3L1 (Chitinase 3-like1), and KLK6 (Kallikrein 6). TNS4 is a focal adhesion protein involved in cell adherence
to extra-cellular matrix substrates (Bockholt & Burridge, 1993). CHI3L1 is expressed
during intestinal inflammation, and enhances bacterial cell invasion into intestinal
mucosa (Mizoguchi, 2006). KLK6 degrades extracellular matrix and may enhance the
metastatic potential of tumor cells (Ghosh et al, 2004). All three of these genes are
involved in attachment to and degradation of basement membrane, thus may encourage
migration, invasion, or seeding of tumor cells at distant sites. It may be determined
whether these genes play a role in the ability of LIN28B to promote migration, invasion,
and metastasis by inhibiting each (via an si-RNA approach, for example) in colon cancer
cells constitutively expressing LIN28B, and conducting migration, invasion, and
xenograft assays. If the ability of LIN28B to promote migration, invasion, and/or
metastasis is dependent on any one of these genes, one would expect knockdown to
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ameliorate the LIN28B-mediated effects. Of note, KLK6 is a predicted let-7 target,
containing several conserved (although poorly) let-7 binding sites (Griffiths-Jones et al,
2006; Griffiths-Jones et al, 2008; Grimson et al, 2007; Lewis et al, 2005; mirBase, 2010;
TargetScan, 2010); thus, the ability of LIN28B to increase KLK6 may is likely mediated
via let-7 repression. However, TNS4 and CHI3L1 are not predicted let-7 targets, thus their
regulation by LIN28B may represent additional let-7 independent functions (GriffithsJones et al, 2006; Griffiths-Jones et al, 2008; Grimson et al, 2007; Lewis et al, 2005;
mirBase, 2010; TargetScan, 2010).
Tumors expressing LIN28B are not only capable of metastasis, they exhibit
increased expression of the intestinal stem cell markers LGR5 and PROM1. Both LGR5
and PROM1 have been implicated previously in colon tumorigenesis: adenomas may
arise in the colon from PROM1+ crypt cells (Zhu et al, 2009), and overexpression of
LGR5 in colon tumors correlates with advanced cancer, invasion, and metastasis (Uchida
et al, 2010). LGR5 and PROM1 up-regulation with LIN28B overexpression may be
consistent with the emerging principle that stem cells are involved in maintenance of
tumors. Intriguingly, targeting stem cells within colon tumors is potentially an effective
therapeutic strategy, and LIN28B may serve as a potential marker of tumors to be targeted
using this approach.

LIN28B in cellular re-programming
It is atypical for genes that promote tumorigenesis to simultaneously enhance
differentiation. Thus, it is difficult to reconcile our findings that primary tumors
constitutively expressing LIN28B are smaller and more differentiated than their empty
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vector counterparts, yet metastasize more frequently. Considering the role of LIN28 in
induction of pluripotency, we hypothesize that LIN28B tumors appear more differentiated
as a result of cellular re-programming. Given that constitutive LIN28 expression in
undifferentiated cells blocks gliogenesis in favor of neurogenesis (Balzer et al, 2010), it is
plausible that LIN28B expression restricts cells to a particular cell fate. Alternatively, the
presence of high LIN28B may induce pluripotency, causing cells to dedifferentiate into
stem cells, with subsequent differentiation into default lineages.
A similar phenotype has been described in the intestinal epithelium where loss of
the Math1 (also called Atoh1) transcription factor leads to depletion of goblet,
enteroendocrine, and Paneth cells, while permitting enterocyte differentiation (Yang et al,
2001). One could address whether LIN28B is accelerating differentiation or inducing
pluripotency in epithelial cells via co-expression of Math1 in cells constitutively
expressing LIN28B, and monitoring the frequency at which cells commit to secretory
lineages. An in vitro approach might involve fetal colonic epithelial cells, which are
capable of differentiating to colonocytes, goblet, and enteroendocrine cells when grown
in standard two-dimensional or organotypic culture (Kalabis et al, 2008; Kalabis et al,
2003).
The ability of LIN28B to induce LGR5 and PROM1 expression also suggests
potential functions of LIN28B in intestinal and colonic epithelial stem cells. Within the
intestine, expression of the cell surface protein PROM1 is restricted to the crypt and
adjacent epithelial cells (Snippert et al, 2009), while expression of the orphan receptor
LGR5 occurs exclusively in cycling columnar cells within the crypt base (Barker et al,
2007). Since co-expression of LGR5 and PROM1 marks intestinal and colonic epithelial
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stem cells, upregulation of these factors by LIN28B suggests a possible role for LIN28B
in establishment and/or maintenance of intestinal stem cells, or in modulating cell fate
decisions.
LIN28B may modulate cell fate decisions via regulation of IGF2 expression.
LIN28 plays a role in both neurogenesis and myogenesis through its ability to promote
IGF2 transcription (Balzer et al, 2010; Polesskaya et al, 2007). IGF2 is involved in
differentiation of variety of cell types, including osteoblasts and mesenchymal cells
(Hamidouche et al, 2010). Loss of IGF2 imprinting, which results in increased IGF2
expression, shifts the intestinal epithelium toward a less differentiated state and increases
expression of the intestinal stem cell marker Musashi 1 (Sakatani et al, 2005). It is
possible that LIN28B induces dedifferentiation and expression of the intestinal stem cell
markers LGR5 and PROM1 by relieving let-7-mediated repression of IGF2BP1, thereby
stabilizing IGF2 mRNA and increasing its translation. Accordingly, it would be
interesting to determine whether IGF2 is required for LIN28B’s function by inhibiting
IGF2 in cells that constitutively express LIN28B and subsequently evaluating LGR5 and
PROM1 expression. If IGF2 is required for the ability of LIN28B to induce
dedifferentiation, or increase LGR5 and PROM1 transcription, one would expect the
absence of IGF2 to eliminate these effects.

LIN28B in epithelial-mesenchymal transition
Epithelial-mesenchymal transition (EMT) is a program of cellular development
characterized by loss of cell adhesion and increased cell mobility, and exemplified by
decreased E-cadherin with concomitant increased vimentin and N-cadherin (Roussos et
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al, 2010; Singh & Settleman, 2010). EMT occurs during normal embryogenesis, but may
be re-initiated in cancer cells resulting in invasion and metastasis (Roussos et al, 2010;
Singh & Settleman, 2010). We find that constitutive LIN28B expression fosters
migration, invasion, and metastasis, all of which suggest roles for LIN28B in epithelialmesenchymal transition (EMT).
TGF-β (Transforming growth factor-beta) promotes EMT in normal cells, and
supports EMT-mediated metastasis in tumors (Singh & Settleman, 2010; Wendt et al,
2009). Constitutive LIN28B expression up-regulates the TGF-β pathway target TGFBI
(Transforming growth factor β-induced, also called BIGH3) as determined by our
microarray analysis. This suggests that increased TGF-β signaling activity may occur
with constitutive LIN28B expression. Moreover, TGF-β induces the let-7 target HMGA2
during EMT (Thuault et al, 2006), further linking TGF-β signaling and EMT with
LIN28B. Conceivably, TGF-β signaling is a mediator of LIN28B-associated EMT and
metastasis.
In order to elucidate the roles of LIN28B in EMT, one might first determine
whether changes in E-cadherin, vimentin, and N-cadherin occur with constitutive LIN28B
expression. Additionally, it could be determined whether TGF-β pathway activation
occurs with constitutive LIN28B expression by assessing phosphorylation of SMAD
transcription factors in LIN28B-expressing cells; SMAD proteins are the transducers of
extracellular TGF-β signaling, thus, an increase in their phosphorylation signifies TGFβ pathway activation (Heldin et al, 1997; Nakao et al, 1997). Provided a link exists
between LIN28B and TGF-β signaling, disrupting it may constitute a novel therapeutic
strategy for colon cancer treatment.
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Murine models as tools for further elucidating roles of LIN28B in
intestinal development and tumorigenesis
Genetically engineered mice would offer excellent resources for fully elucidating
the roles of LIN28B in colon development and tumorigenesis. To that end, flanking loxP
sites may be engineered into the mouse LIN28B locus; alternatively, one might consider
introducing mutations that disrupt specific functions of LIN28B, such as its ability to bind
RNA or inhibit let-7 biogenesis. Targeted deletion of LIN28B in the colon would allow
one to determine the requirement, if any, of LIN28B in intestinal development. We
hypothesize a central role for LIN28B in intestinal cell fate decisions and thus, we
hypothesize deletion or expression of functionally null LIN28B mutants in the colon
would result in a vastly perturbed or absent intestinal epithelium. Correspondingly, one
might expect deletion of LIN28B in the colon to inhibit or delay tumor formation, which
may be determined by interbreeding LIN28B knockout mice with existing mouse models
of colon cancer (Taketo & Edelmann, 2009).
Roles of LIN28B in colon organogenesis and tumorigenesis may also be evaluated
via constitutive expression in the colon. This may be achieved by creating a conditionally
activated transgene to drive LIN28B transcription. Spatially controlled conditional
activation of gene expression has been achieved in the past by employing a lox-STOP-lox
cassette, which effectively prohibits expression of a gene of interest until the cassette is
excised (Olive et al, 2004; Tuveson et al, 2004). Genetically engineered mice in which
constitutive LIN28B transcription is subjected to the control of a lox-STOP-lox cassette
would be useful tools in determining the contributions of LIN28B to intestinal
differentiation. Using this model, one could target LIN28B overexpression to the
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intestinal epithelium by via cre-mediated excision of the lox-STOP-lox cassette, which
may achieved by cross-breeding with Fabp1-cre or Villin-cre or mice (el Marjou et al,
2004; Wong et al, 2000). Major benefits of this approach over traditional transgenic
models include the ability to activate LIN28B overexpression in adult mice (using CreERT), and to expand studies of LIN28B to other tissues (by taking advantage of the vast
array of Cre transgenes that exist). Conversely, one could place LIN28B under the direct
control of the Villin promoter (currently being done in the lab). Based on the results of
our xenograft tumors, one might expect increased LIN28B expression in the colonic
epithelium to alter the secretory lineage. In addition, targeting LIN28B overexpression in
the colonic epithelium may accelerate progression of adenocarcinomas in existing mouse
models of colon cancer, thereby creating a valuable murine model of metastatic colon
cancer.
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Conclusions
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We have demonstrated reduction in mature let-7a and let-7b levels in colon
tumors as compared to matched adjacent normal colonic epithelium. Subsequently, we
demonstrated potential tumor suppressive properties of let-7a and let-7b via constitutive
expression of a let-7a-3-b pri-microRNA in colon cancer cell lines. Increased expression
of let-7a and let-7b represses let-7 targets, while decreasing cell migration and invasion
in vitro.
Reduced levels of let-7a and let-7b in colon tumors correlate with increased
expression of the let-7 inhibitor, LIN28B. We have demonstrated that overexpression of
LIN28B occurs in approximately 50% of colon tumors, and that high Lin28b in early
stage colon cancer correlates with increased probability of recurrence and reduced patient
survival.
Constitutive LIN28B expression in immortalized colonic epithelial and colon
cancer cell lines promotes cell migration, invasion, and transformation in vitro. In
addition, constitutive LIN28B expression modulates levels of a number of mRNA
transcripts, including let-7 targets, and the intestinal stem cell markers LGR5 and
PROM1, which are not predicted let-7 targets. Restoration of let-7 levels in cells
expressing LIN28B constitutively ameliorates some, but not all of these described effects,
thereby suggesting let-7 independent functions of LIN28B. Additionally, roles for
LIN28B in cellular reprogramming and metastasis are suggested by constitutive LIN28B
expression in vivo, which results in more differentiated xenograft tumors that display a
metastatic phenotype.
The overarching hypothesis of this work, LIN28B promotes tumorigenesis via
suppression of let-7 in the colon, appears to be correct and highlights the importance of
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both let-7 and LIN28B in the molecular pathogenesis of colon cancer. This novel work
suggests roles for let-7 dependent and independent functions of LIN28B in cell migration
and invasion, modulation of gene expression, cellular reprogramming, and tumor
metastasis. Future studies will elucidate further LIN28B’s functional roles in colon cancer
through generation of genetically engineered mice.
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